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This work describes the fascinating interplay between two tumor suppressors 
Prostate apoptosis response-4 (Par-4) and p53. The guardian of the genome, 
p53, is frequently mutated in human cancers, and may contribute to therapeutic 
resistance. However, p53 is intact and functional in normal tissues, and we 
observed that specific activation of p53 in normal fibroblasts could induce 
apoptosis selectively in p53-deficient cancer cells. This paracrine apoptotic effect 
was executed by Par-4 secreted in response to p53 activation. Accordingly, 
activation of p53 in wild-type mice, but not in p53-/- or Par-4-/- mice, caused 
systemic elevation of Par-4 that induced apoptosis of p53-deficient tumor cells. 
Mechanistically, p53 induced Par-4 secretion by suppressing the expression of 
UACA (Uveal Auto-antigen with Coiled-coil domains and Ankyrin repeats), a 
binding partner of Par-4, and thereby releasing Par-4 from sequestration by 
UACA. Thus, normal cells can be empowered by p53 activation to induce Par-4 
secretion for inhibition of therapy-resistant tumors.  
Conversely, our studies have also revealed a definite role for Par-4 in regulating 
p53 expression. The pro-apoptotic tumor suppressor Par-4 is lost, down-
regulated, inactivated or mutated in a number of cancers. Loss of Par-4 is 
associated with therapeutic resistance and poor disease prognosis, yet the 
mechanism for resistance is not clearly understood. Using genetically matched 
cells, we show that Par-4 expression is required for stabilization and function of 
the tumor suppressor p53, which constitutes the hub of signaling networks 
controlling important cellular and organismal phenotypes. In particular, the 
expression of p53 protein and its stabilization in response to genotoxic stress 
were remarkably attenuated in response to Par-4 loss.  Accordingly, Par-4-null or 
-knockdown cells demonstrated increased resistance to apoptosis induced by 
genotoxic stress. Par-4 loss resulted in elevated Mdm2 activity, which is known 
to cause p53 degradation. Our findings suggest that Par-4 stabilizes p53 by 
inhibiting Akt-mediated phosphorylation of Mdm2 that is known to prevent 
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translocation of Mdm2 into the nucleus for p53 ubiquitination and degradation. 
These studies identify a novel regulatory relationship between two tumor 
suppressors and may provide a better understanding of therapeutic resistance in 
tumors with p53 wild type status. 
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CHAPTER ONE: INTRODUCTION 
 
In the United States, cancer is ranked second only to heart disease in terms of 
the total number of deaths; and, in adults belonging to the age group 40-79 
years, it is the leading cause of death (Siegel et al., 2014). According to the 
report prepared by the International Agency for Research in Cancer (IARC), 
cancer is the leading cause of mortality worldwide- an estimated 8.2 million 
deaths was caused by cancer alone in 2012. Furthermore, cancer cases are 
projected to increase by 75% globally, and reach close to 25 million over the next 
two decades (World Cancer Report 2014). The global burden of cancer 
continues to increase, and represents one of the most formidable public health 
problems. 
Extensive research in the field of cancer biology over the past few decades has 
made it possible to appreciate the remarkable diversity and intricate complexities 
found within this disease. It is now widely accepted that tumorigenesis involves a 
multi-step process leading to an accumulation of genetic aberrations. Many adult 
human tumors reflect 4-7 rate-limiting, stochastic mutation events. Often such 
changes reflect a dominant gain of function in oncogenes, or a recessive loss of 
function in the case of tumor suppressors, which lead to defects in cellular 
regulatory processes that enable them to override cell cycle control checkpoints, 
and escape apoptosis, thus tipping the balance in favor of uncontrolled growth 
and proliferation. According to the model projected by Hanahan and Weinberg, 
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individual tumors will sustain as many mutation events, in as many genes, as are 
necessary to acquire the six traits that today are famously known as the 
“hallmarks of cancer”. These six hallmarks are: a) self-sufficiency in growth 
signals; b) insensitivity to growth-inhibitory cues; c) evasion of programmed cell 
death (apoptosis); d) limitless replicative potential; e) sustained angiogenesis; 
and f) tissue invasion and metastasis (Hanahan and Weinberg, 2000). In 
addition, in recent times, the role of a supportive microenvironment in 
tumorigenesis is being increasingly appreciated. Earlier perceptions of a tumor 
as an insular mass of transformed cells has given way to the concept of tumor as 
an assemblage of distinct, specialized cell types and sub-types, which 
collectively constitute a complex tumor microenvironment in which the dynamic 
interaction between the neoplastic cells (which forms the tumor parenchyma) and 
the mesenchymal compartment (which forms the tumor-associated stroma) is 
believed to be increasingly important for tumor initiation, progression and 
metastasis (Hanahan and Weinberg, 2011). 
TUMOR SUPPRESSOR GENES 
Knudson’s “two-hit theory” following his historical analysis of familial and non-
familial retinoblastomas, the phenomenon of loss of heterozygosity (LOH), and 
his mutational analysis of the Retinoblastoma gene (Rb) thereafter, laid out the 
framework for the classical paradigm for tumor suppressor genes (Friend et al., 
1986; Knudson, 1971). Tumor suppressor genes have been traditionally 
characterized as ‘recessive’ genes, and bi-allelic inactivation of a tumor 
suppressor is considered to be essential for tumorigenesis. Thus, germline 
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mutation in a tumor suppressor gene can be cause of familial cancer syndrome 
that shows an autosomal dominant pattern of inheritance. In addition, the same 
tumor suppressor gene is supposed to be inactivated in a number of sporadic 
cancers.  
A functional classification categorizes tumor suppressors as a) gatekeepers; or 
b) caretakers; or c) landscapers (Kinzler and Vogelstein, 1996, 1998). 
Gatekeeper genes include all genes that have distinct function in cell cycle 
regulation and in suppressing proliferation, promoting differentiation, and 
inducing apoptotic cell death. Examples include APC, Rb1, PTEN, Tp53, Par-4. 
Loss of function of a gatekeeper tumor suppressor is ‘rate-limiting’ for either 
tumor initiation, or progression, or metastasis in multi-stage tumorigenesis. 
“Caretaker” tumor suppressors function by playing pivotal roles in maintaining 
genomic integrity and preventing aberrations such as aneuploidy and 
microsatellite instability. Examples of this class include DNA repair genes such 
as MSH2, MLH1, BRCA1, ATM etc. Disruption of a caretaker gene would lead to 
increased genomic instability and higher mutation rates, thus raising the 
probability of a gatekeeper being inactivated. “Landscaper” genes function by 
regulating the extracellular matrix, or the expression of cell surface markers, or 
by modulating the action of secreted proteins/growth factors, thus controlling the 
tumor microenvironment (Kinzler and Vogelstein, 1996, 1998; Macleod, 2000). 
For the purpose of this dissertation, we will focus on apoptosis (or lack thereof) in 
cancer, and on the tumor suppressor genes that target apoptotic pathways as a 
means to cause tumor suppression and achieve tissue homeostasis.  
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APOPTOSIS 
Apoptosis is a highly organized complex process of programmed cell death that 
utilizes the cellular machinery of gene transcription and translation in order to get 
rid of damaged or superfluous cells. Apoptosis is characterized by distinct 
morphological features such as chromatin condensation, DNA fragmentation, 
membrane blebbing, preservation of organelle structure, and containment of 
cellular contents within membrane-bound apoptotic bodies (Kerr et al., 1972).  
Apoptotic cell death in vertebrates usually occurs via one of the two- extrinsic or 
intrinsic- pathways, both of which ultimately utilize the aspartate-specific cysteine 
protease (caspase)-mediated proteolytic cascade. Extrinsic (death receptor-
initiated) pathway is triggered by the interaction of extracellular signals with cell 
surface death receptors of the CD95 (Apo-1 or Fas)/TRAIL/TNF receptor 1 
family, or Death Receptors 3, 4 and 5 (DR3, DR4, DR5), which often leads to 
receptor clustering and recruitment of the adaptor protein Fas-activated Death 
Domain (FADD) to the intracellular effector domain of the death receptor. FADD 
proteins in turn recruit initiator procaspase 8 to form a death inducing signaling 
complex (DISC).  
The intrinsic (or mitochondrial) apoptotic pathway is regulated by the Bcl-2 family 
of proteins, which promote or inhibit the apoptotic process by governing the 
activation/inactivation of mitochondrial permeability transition pore (MPTP). 
Based on functional relevance, this family is sub-divided into two groups:  
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a) Anti-apoptotic group includes Bcl-2, Bcl-xL, Mcl-1, A-1, and Bcl-W- 
molecules that are essential for cell survival.  
b) Pro-apoptotic group is represented by proteins such as Bax and Bak, 
which, among others, are essential for mitochondrial outer membrane 
permeability (MOMP). Other pro-apoptotic members of this family, namely, 
PUMA, Noxa, Bim, Bad and Bmf act by sequestering Bcl-2 and Bcl-xL, 
and thereby inhibiting the action of these anti-apoptotic molecules. 
In response to apoptotic cues such as cytotoxic stresses or developmental 
signals, Bax and Bak, the pro-apoptotic members of Bcl-2 family, can homo- or 
hetero-dimerize with other pro-apoptotic partners of the Bcl2 family to form pores 
on the outer mitochondrial membrane, and thereby trigger the release of 
apoptogenic molecules (such as cytochrome c, Smac/DIABLO) from the 
mitochondria into the cytosol, leading to the formation of a procaspase-activating 
adaptor protein called apoptotic protease activating factor-1 (Apaf1). Apaf1 then 
recruits and activates procaspase 9. Activation of both caspases 8 and 9 
unleashes the caspase cascade by activating downstream executioner caspases 
(caspase-3, -6, and -7) to ultimately result in apoptosis of the cell by causing the 
release of the endonuclease caspase-activated DNAse (CAD) from its inhibitor 
iCAD, and by proteolytic cleavage of key cellular enzymes and proteins 
(Delbridge et al., 2012; Strasser et al., 2000).  
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Apoptosis and cancer 
As early as 1972, Kerr et. al. speculated that apoptosis, a highly regulated 
process of “cell deletion”, was crucial to maintaining normal tissue homeostasis. 
In addition, they theorized that this “cell loss factor” or apoptosis played a vital 
role in counter-balancing the rapid rate of mitosis in neoplastic growth, and the 
resulting equation between these two processes determined the rate of tumor 
enlargement. They also proposed that apoptosis may be involved in tumor 
regression following therapeutic intervention (Kerr et al., 1972). Subsequent 
studies revealed a high rate of apoptosis in spontaneously regressing tumors, as 
well as in tumors treated with cytotoxic anti-cancer agents (Kerr et al., 1994). 
Cloning, characterization, and recognition of Bcl-2 proto-oncogene (activated by 
chromosomal translocation) in B-cell follicular lymphomas consolidated the 
proposition that, apart from “transforming” or “immortalizing” hyper-proliferative 
phenotype that oncogenes were heretofore attributed with, oncogenes like Bcl-2 
could promote tumor growth by blocking programmed cell death or apoptosis 
(Lowe and Lin, 2000). Likewise, many human cancers demonstrate up- or down-
modulation in the expression and/or functions of key molecules involved in the 
apoptotic process at multiple layers of regulation, thus promoting incongruous 
cell survival, and contributing to oncogenesis. Overexpression of Bcl-2 is 
observed in non-Hodgkin’s lymphomas, small cell lung cancers, chronic 
lymphocytic leukemia, neuroblastoma and prostate cancer, and this up-regulation 
is also associated with a chemo-resistant phenotype (Reed, 1999; Yip and Reed, 
2008). Bcl-xL is also reported to be over-expressed in multiple myeloma, 
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Kaposi’s sarcoma, colorectal adenocarcinoma, hepatocellular carcinoma, and 
pancreatic cancer (Plati et al., 2011). On the other hand, loss or inactivation of 
the pro-apoptotic members of the Bcl-2 family leads to defects in the apoptotic 
pathway, which, in conjunction with an oncogenic mutation, is potentially 
tumorigenic. For example, homozygous deletion of Bim was found in 
approximately 20% of mantle cell lymphomas; and accordingly, Bim inactivation 
accelerated Eμ-myc-driven lymphomagenesis in mice. Similarly, loss of PUMA in 
mice also results in accelerated lymphoma development in Eμ-myc transgenic 
mice, and PUMA expression is also lost from nearly 40% of Burkitt’s lymphoma. 
In addition, loss of pro-apoptotic Noxa, Bax or Bmf have been shown to promote 
lymphoma development in experimental mouse models, but alterations in these 
genes in human cancers have not yet been reported (Delbridge et al., 2012). 
This shows that deregulation of apoptosis might not exert a potent transforming 
influence; however, it predisposes cells to survive in inappropriate 
circumstances, and sustain other mutation(s) that can then lead to oncogenic 
transformation. 
Dysregulation of the extrinsic or receptor-mediated apoptotic signaling pathway is 
also frequently observed in various cancers. Mutations in Fas or Fas ligand is 
known to promote lympho-proliferation, and therefore constitute a predisposition 
to hematopoietic malignancy in both mice and humans (Drappa et al., 1996; O' 
Reilly et al., 2009; Rieux-Laucat et al., 1995). In addition, many human cancers, 
for example, melanoma, hepatocellular carcinoma, non-small cell lung 
carcinoma, endometrial, colon and prostate cancers show elevated expression of 
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caspase-inhibitory proteins known as c-FLIP (FLICE Inhibiting Proteins), which 
are recruited to the DISC at the cell membrane via their Death Effector Domains 
(DED), and act as Caspase-8 decoys to inhibit its activation, thereby blocking 
death receptor-mediated apoptosis (Plati et al., 2011). 
Another facet of caspase regulation involves the IAP (Inhibitors of Apoptosis) 
family of proteins, composed of eight members, and encoded by genes BIRC1 to 
BIRC-8. Among these, cellular IAP1 (c-IAP1) (BIRC2), c-IAP2 (BIRC3), XIAP 
(BIRC4), and ML-IAP (BIRC7) are directly involved in apoptosis regulation 
whereas the other members modulate cell survival by other means, for instance, 
by cell cycle regulation or inflammation. These IAP molecules inhibit the 
apoptotic process either by directly binding to the caspases and inhibiting their 
activity or by virtue of their ubiquitin ligase activity (de Almagro and Vucic, 2012). 
Over-expression of IAP proteins across a variety of cancers, for example, colon 
cancer, breast cancer, melanomas, clear-cell renal carcinomas etc (de Almagro 
and Vucic, 2012) further emphasize the fact that survival advantage acquired by 
apoptosis inhibition provides an impetus to the tumorigenic process. Mutations in 
caspases are not frequently encountered in cancers. Nevertheless, disruption of 
Apaf-1 is associated with Noonan syndrome; caspase-10 mutations contribute to 
autoimmune lympho-proliferative syndrome type II; and frameshift mutations in 
caspase-5 have been observed in gastrointestinal, endometrial, and in hereditary 
non-polyposis colorectal cancers (Lowe and Lin, 2000). 
The process of apoptosis has evolved as a means to eliminate altered or 
superfluous cells that show tumorigenic potential or otherwise threaten tissue 
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homeostasis. Conversely, transformed/neoplastic cells employ various cellular 
strategies to suppress protective apoptotic response and develop significantly 
increased tolerance to apoptotic stimuli such as growth factor depletion, hypoxia, 
DNA damage, telomere malfunction, activation of mitogenic oncogenes, and 
treatment with radiation or chemotherapy in order to acquire one of the hallmarks 
of cancer- evasion of apoptosis. Some tumor suppressor genes, such as Tp53 
and Par-4, play an integral role in this process of apoptosis, which constitutes a 
critical aspect to tumor inhibition mediated by these tumor suppressors. We will 
elaborate a little bit about these tumor suppressors, p53 and Par-4, whose cross-
talk constitutes the framework of this dissertation.  
TUMOR SUPPRESSOR P53 
The tumor suppressor p53 appears to transcend borders of classification that 
Kinzler and Vogelstein (Kinzler and Vogelstein, 1996) used to define tumor 
suppressors, since p53 can be considered both as a ‘gatekeeper’ for its role in 
cell cycle control and apoptosis; and a ‘caretaker’ in its role as the ‘guardian of 
the genome’. However, it is interesting to note that p53, the product of the gene 
Tp53, was discovered in 1979 as a 53kD protein bound by the large T-antigen 
oncoprotein of the sarcoma-associated virus SV40 in transformed cells and 
tumors, and was postulated to be an oncogene product linked to viral 
transformation process (Lane and Crawford, 1979; Linzer and Levine, 1979). 
Other observations regarding p53 around the same time seemed to support this 
hypothesis. Ten years later, cloning of wild-type p53 cDNA by Finlay et. al., and 
their seminal observation that wild-type p53 prevented transformation of cell 
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cultures by oncogenes began the evolution of p53 as a potential tumor 
suppressor (Finlay et al., 1989).  
Tumor suppression by p53 
Functional studies on Tp53 performed in the decade of 1980’s led to the notion 
that p53 behaved as a proto-oncogene. It was not only found complexed with 
viral oncoproteins, but was observed to be over-expressed in tumor-derived and 
transformed cell lines. Moreover, isolation of several cDNA clones showed that 
p53 had the potential to transform cells in combination with the Ras oncogene 
(Levine et al., 2004). However, the evidence for its supposed oncogenic potential 
was later realized to be erroneously collected from mutant p53 cDNA clones. 
Finlay et. al. demonstrated that the wild-type p53 cDNA actually blocked the 
transformation process driven by the oncogenes E1A plus Ras, as well as those 
initiated by mutant p53 plus Ras. They also observed that cells that were 
transformed in culture selected for mutated p53, and that mutant p53 not only 
lost its tumor suppressive ability, but could act in a dominant negative fashion to 
inactivate wild-type p53, thus making an unambiguous case for the tumor 
suppressive effects of wild-type p53 (Finlay et al., 1989). Indeed, mutations in 
both alleles of Tp53 were identified in mouse tumors and in cultured human cell 
lines; and in human colorectal cancers, wild-type Tp53 alleles were frequently 
observed to be lost by mutations and/or deletions: all of these being definite 
indications of a candidate tumor suppressor (Lane and Levine, 2010). 
The ensuing upsurge of interest in p53 research continued to bring forth more 
evidence in support of the tumor suppressive actions of p53. By 1992, p53 was 
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clearly established as a check-point protein involved in cell cycle arrest and in 
maintaining genomic integrity following DNA damage (Lowe and Lin, 2000). 
Studies with knock-out mouse models have demonstrated that mice deficient in 
p53, in spite of being developmentally normal, spontaneously develop cancer 
(particularly lymphomas and sarcomas) with high penetrance at a very young 
age (Donehower et al., 1992; Jacks et al., 1994). P53 knock-out mice are also 
more susceptible to oncogene- or carcinogen-induced tumors (Donehower and 
Lozano, 2009). Additionally, transgenic mice engineered to over-express p53 
were shown to be significantly resistant to cancer, thus emphasizing the tumor-
protective effects of p53 (Garcia-Cao et al., 2002).  
Substantive evidence from human cancers and cancer-derived cell lines has also 
served to conclusively establish p53 as a bona-fide tumor suppressor. Germline 
Tp53 mutations are known to cause a rare type of cancer predisposition called 
the Li-Fraumeni syndrome. Li-Fraumeni patients with an inherited mutant allele of 
Tp53 show an increased susceptibility to early-onset cancers of diverse types 
(Levine and Oren, 2009). Approximately 50% of all sporadic human tumors show 
mutations in both alleles of Tp53 gene, and more than 25,000 Tp53 mutations 
have been identified so far, making it the most frequently mutated gene in all 
human cancers. Moreover, both germline and somatic mutations at the Tp53 
locus are usually followed by loss of heterozygosity (LOH) during tumor 
progression, suggesting that a selective force inactivates wild-type p53 in the 
process (Brosh and Rotter, 2009). Furthermore, p53 mutations are often 
associated with advanced tumor stage and poor patient prognosis (Wallace-
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Brodeur and Lowe, 1999). Approximately 75% of all p53 mutations are missense 
substitutions. Mutant p53 tends to be more stable than wild-type p53 (hence the 
aberrant over-expression observed in tumors). Most common p53 mutants are 
known to exert tumor-promoting effects by dominant negative inactivation of 
endogenous wild-type p53, in addition to oncogenic gain of function activities. It 
is now known that abrogation of wild-type p53 transcriptional activity is the key 
factor in the selection of such missense mutations. Not surprisingly, majority of 
p53 missense mutations occurs in the DNA binding domain (DBD), thus 
impacting its transactivation capacity which is crucial for its tumor suppressive 
functions (Brosh and Rotter, 2009; Petitjean et al., 2007). The structure of p53; 
and its central role in eliciting a transcriptional program that can control critical 
cellular processes (such as cell cycle arrest, cellular senescence and apoptosis) 
that bring about tumor suppression are briefly discussed below. 
Structure 
P53 protein, a stress-induced transcription factor, is biologically active as a 
homo-tetramer comprising 4 x 393 amino acid residues; each monomer 
consisting of 393 amino acids, and representing a highly modular structure of 
intricate complexity. P53 contains folded DNA-binding and tetramerization 
domains flanked by intrinsically disordered regions at both amino (N)- and 
carboxy (C)-termini. N-terminus of p53 comprises the transcription-activation 
domain (TAD) (residues 1–62), which is essential for p53 transcriptional activity. 
The p53 TAD connects target gene recognition to its expression by directly 
binding to the transcriptional co-activators p300/CBP and components of the 
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basic transcriptional machinery. It can be further divided into sub-domains TAD1 
and TAD2, which is followed by a proline rich domain (PRD) (residues 63-94) 
(Joerger and Fersht, 2010). TAD2 is shown to be essential for transcriptional 
activation of a number of target apoptotic genes. In addition, the PRD is 
considered necessary for apoptosis and growth suppression mediated by p53 
(Harms and Chen, 2005). 
Amino acid residues (94-292) in the p53 protein confer DNA-binding potential, 
and therefore, constitute its “core” domain. This core domain is responsible for 
recognizing and binding to its target duplex DNA in a sequence-specific manner, 
and is also involved in co-repressor binding. The p53 binding-site sequence 
consensus is discussed in more detail in forthcoming sections below. Nuclear 
entry of p53 is regulated by a nuclear localization signaling domain (residues 
316-324).  Moreover, residues 325-355 are involved in p53 tetramerization, 
which is essential for its activity in vivo. Residues 356-393 of p53 form the basic 
C-terminal domain (CTD) which performs important regulatory functions, and is 
involved in down-modulation of DNA-binding activity of p53 core domain (Harms 
and Chen, 2005; Joerger and Fersht, 2010). 
P53 also interacts with a large number of protein partners, and a majority of its 
interactions are mediated through its N-terminal TAD, although a good number of 
partners also interact with the C-terminal domain, and only a few bind to the core 
domain (Joerger and Fersht, 2010). In addition, within the N-terminal and C-
terminal domains of p53 reside a multitude of amino acid residues subject to an 
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array of post-translational modifications that can modulate p53 activation, 
stabilization, as well as binding to its partners.  
Transcriptional regulation by p53 
More than three decades of research in the field of p53 has revealed that a broad 
range of cellular processes are regulated by p53, and continues, to this day, to 
ascribe new roles for p53 in the regulation of metabolism, autophagy, fecundity, 
and various aspects of differentiation and development. The best characterized 
function of p53 is that of a pivotal signaling node that translates diverse upstream 
stress signals into downstream responses including, but not limited to, cell cycle 
arrest, senescence, and apoptosis. As a transcriptional factor, p53 regulates the 
expression of several critical molecules necessary to co-ordinate these multiple 
aforementioned processes that produce anti-proliferative and anti-transformation 
outcomes. Thus transcriptional regulation of its target genes by p53 is integral to 
its role as a tumor suppressor. 
Extensive research in the p53 field over the years has identified an estimated 
several hundreds of RNA-polymerase II (RNAP II)-transcribed genes that are 
directly, and thousands others that are indirectly, regulated by p53 (Beckerman 
and Prives, 2010). Although p53 mRNA is constitutively expressed, basal levels 
of p53 protein are kept extremely low in unstressed cells. A plethora of cellular 
stresses, including but not limited to, genotoxic stresses such as radiation, 
telomere erosion, nucleotide depletion; hypoxia; heat/cold shock; nutritional 
starvation; mitochondrial biogenesis stress; oncogenic activation etc, can 
stabilize and activate p53. Stabilization of p53 expression levels primarily occurs 
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through events that disrupt its interaction with its negative regulator Mdm2 
protein, which mediates the proteasomal degradation of p53.  
Once stabilized, p53 translocates into the nucleus and binds, as a tetramer, 
specific DNA sequences that are designated p53 response elements (REs) 
(McLure and Lee, 1998). The consensus p53-binding DNA sequence consists of 
two copies of the 10-base pair motif RRRCWWGYYY (n=0-13) RRRCWWGYYY 
(where R is Adenine or Guanine, W is a purine base, and Y is a pyrimidine base) 
with or without a spacer region (n), which can be up to 13 bases long. C4 and G7 
in each motif are considered critical for effective binding (el-Deiry et al., 1992; 
Funk et al., 1992). However, an analysis of functional p53 target genes suggests 
that mismatches in one or more bases in the consensus sequence do not result 
in loss of binding. Non-canonical sites, such as those found in pig3 (TGYCC)n 
response microsatellite element; the triplet pairs of the pentameric element at the 
aqp3 locus; or the “head-to-tail” configuration of the Mdr1 site show that p53 REs 
can accommodate moderate alterations in the consensus sequence (Beckerman 
and Prives, 2010). 
P53 REs are usually found to cluster in the non-coding areas of its target gene, 
and are most commonly found in the promoter at varying distances upstream 
(e.g., p21, noxa) of the transcription start site (TSS), although some might be 
located closer (within 300 base pairs) of the TSS (e.g. Hdm2, Pcna). However, 
these REs have also been found at diverse regions within the target gene locus; 
for instance, within early intronic sequences (e.g. Puma, Pig3), and also within 
exons (e.g. miR-34a). Once bound to its RE, p53 can then recruit diverse 
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transcriptional co-regulators, such as histone modifying enzymes, chromatin 
remodeling complexes, and components of the general transcriptional machinery 
and the pre-initiation complex (PIC) to modulate RNAP II activity at the target 
gene locus.  
Although majority of research has focused on p53 as a transcriptional activator, 
p53 can also cause repression of some of its target genes. It is yet not clear what 
distinguishes an RE from being a transcriptional activator-site versus a 
transcriptional-repressor site. Nonetheless, p53 is considered to cause gene 
repression via the following three generally accepted mechanisms (Riley et al., 
2008): 
i. Steric interference, wherein p53 binding to its RE overlaps the binding 
site of another (more powerful) trans-activating agent (e.g. Afp, Bcl-2). 
ii. P53 squelching of transcriptional activators (e.g. cyclin B1, TERT). 
iii. P53-mediated recruitment of transcriptional co-repressors, such as 
histone deacetylases (HDACs) (MAP4, Hsp90AB1) (Riley et al., 2008). 
Diverse cofactors that interact with, or are recruited to specific RE’s by p53, can 
post-translationally modify histones, other cofactors, or p53 itself. The precise 
mechanisms whereby p53 targets a select group of genes regulating a specific 
pathway in response to distinct stresses are poorly understood. However, it is 
now thought that combinations of cofactors and post-translational modifications 
(e.g. phosphorylation, acetylation, sumoylation, neddylation etc) may serve as 
distinct “barcodes” to enable the selection of specific promoters. P53 thus 
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regulates a number of genes directly involved in the control of the following 
cellular processes that are considered to be the mechanisms for tumor 
suppression by p53: most notably cell cycle arrest, senescence, and apoptosis. 
P53-mediated transactivation of p21Waf1/Cip1 is considered important for G1/S 
arrest; and repression of Cdc25c, in addition to activation of 14-3-3σ can initiate 
G2/M arrest (Zilfou and Lowe, 2009). P53 and its downstream effectors can 
initiate a program of cellular senescence leading to a terminal state for the 
replication of cells. Many studies have emphasized the importance of 
senescence in the inhibition of tumor progression, and have identified a key role 
for p53 and p53-regulated genes p21Waf1/Cip1 and Plasminogen Activator Inhibitor- 
1 (PAI- 1) in this process (Vousden and Prives, 2009).  
P53 and apoptosis 
Incidentally, p53 was the first tumor suppressor to be linked to apoptosis, and 
this aspect of p53 function constitutes one of the most extensively researched 
areas in the field. Endogenous p53 has been shown to be essential for radiation-
induced apoptosis in mouse thymocytes (Lowe et al., 1993b). Marked reduction 
in apoptosis correlates with the occurrence of some p53 mutations in transgenic 
mice, and with clonal progression in Wilm’s tumor (Lowe and Lin, 2000). Studies 
using p53 knock-out mice have demonstrated that p53 plays a critical role in 
apoptosis induced by a range of stimuli, including DNA damaging anti-cancer 
agents, radiation, hypoxia, and mitogenic oncogenes. On the other hand, mice 
expressing a p53 mutant protein that lacks the ability to induce cell cycle arrest, 
but retains apoptotic potential are efficiently protected from spontaneous tumor 
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development (Toledo et al., 2006). P53 regulates the promoters of numerous 
genes involved in apoptosis. Upon activation, p53 transactivates various pro-
apoptotic effectors of both intrinsic and extrinsic apoptotic pathways, including 
Noxa, PUMA, Bax, PIG3, p53AIP1, Perp, CD95 and DR5 (Zilfou and Lowe, 
2009). In addition, disruption of several p53 effectors, such as, Bax, Apaf-1 and 
Caspase-9 can promote oncogenic transformation and tumor development in 
mouse models (Lowe and Lin, 2000).  
Apart from these transcription-dependent actions, p53-mediated apoptosis also 
involves its transcription-independent functions. Specifically, in response to some 
cell death signals, such as IR, p53 rapidly localizes to the mitochondria, where it 
can induce mitochondrial outer membrane permeabilization (MOMP), thus 
effecting the release of pro-apoptotic factors from the mitochondrial inter-
membrane space. Additionally, p53 is known to bind Bcl-2, Bcl-xL, and Bak at the 
mitochondria, acting either as a direct activator of the pro-apoptotic Bax and/or 
Bak, or as a derepressor. P53-regulated apoptosis effector molecule PUMA 
appears to be the link between transcription-dependent and -independent 
mechanisms of p53-mediated apoptosis. PUMA, which is directly up-regulated by 
p53 in response to cellular stress, translocates into the mitochondria where it 
interact with Bcl-xL, thus releasing p53 to activate Bax (Zilfou and Lowe, 2009).  
Many more p53 target genes have been implicated in apoptosis than in other 
effector functions, suggesting that its control of the apoptotic response is 
complex. P53 simultaneously targets multiple death circuit pathways to co-
ordinate an apoptotic response, and hence, no single p53-regulated molecule 
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can account for all of its pro-apoptotic activity. This fact is exemplified by PUMA, 
which is considered to be essential for apoptosis induction by p53, and is the 
only p53 target gene whose loss produces apoptotic defect similar to that caused 
by p53 loss in irradiated T lymphocytes. Yet, PUMA-null mice do not exhibit the 
overt tumor-prone phenotype like their p53-null counterparts do, implying that 
multiple effector functions of p53, rather than just disruption of apoptosis, must 
be simultaneously inactivated to initiate tumorigenesis and that the end result of 
p53 activation is context-dependent. Apoptosis can be integrated into a larger 
p53 tumor suppressor network controlled by different signals, environmental 
contexts, and cell type (Fridman and Lowe, 2003; Zilfou and Lowe, 2009).  
Non-autonomous tumor suppression by p53 
Although most of the extensive research on p53 has concentrated on the cell 
autonomous role of p53 in tumor suppression, emerging evidence also points 
towards non-cell autonomous tumor suppressive effects of p53. Many studies 
have explored p53 status in the tumor mesenchyme, particularly in the 
supporting fibroblasts that constitute the supporting stroma, and concluded that 
p53 can inhibit tumorigenesis and tumor progression in a non-cell autonomous 
manner. High frequencies of somatic mutations in Tp53 have been reported in 
breast neoplastic epithelium and stroma (Kurose et al., 2002). There is also 
evidence that tumor latency is reduced in p53-null mice relative to wild-type mice, 
indicating that the presence of wild-type p53 in the host exerts an inhibitory effect 
on tumor progression. In addition, reconstitution of tumors with either wild-type or 
p53-/- MEFs in mice showed accelerated tumor growth in the presence of p53-null 
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fibroblasts, even though the composition differed only in p53 status of fibroblasts, 
the neoplastic component being identical (Kiaris et al., 2005). This reinforces the 
idea that p53 loss produces a supportive stroma that is more conducive to tumor 
growth. Moreover, tumor progress imposes a strong selective pressure for loss of 
p53 function in cancer-associated fibroblasts (CAFs), and stromal cells frequently 
show LOH at the Tp53 locus, similar to those found in primary tumors (Hill et al., 
2005; Kiaris et al., 2005; Kurose et al., 2002). 
P53 and cancer therapy 
Because of its control of multiple arms in the apoptotic process, the p53 pathway 
can influence tumor responsiveness to therapeutic agents. Numerous cell culture 
and in vivo studies have demonstrated that tumors that are wild-type for p53 
undergo p53-dependent apoptosis when treated with a wide variety of 
therapeutic agents, such as IR, Adriamycin, 5-Fluorouracil (5-FU), Etoposide, 
Vincristine (Dudley et al., 2008; Levine, 1997; Lowe et al., 1994; Lowe et al., 
1993a; Mirzayans et al., 2013), and p53 loss/inactivation leads to resistance to 
apoptosis of tumor cells in response to such agents. Additionally, cytogenetic 
changes in tumor stroma including p53 mutations can compromise p53 function, 
and modulate response to chemotherapy. Tumor-associated stromal cells have 
been reported to show diminished p53 accumulation and decreased sensitivity to 
the effects of p53-activating agents such as Etoposide and Vincristine (Dudley et 
al., 2008) . 
In view of such far-reaching tumor suppressive effects of p53, much scientific 
effort has been channelized to reinstate p53 pathway in tumors with the help of 
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gene therapy or using strategies to reactivate p53 in tumor cells, in order to 
restore responsiveness to therapy and improve patient prognosis (Vousden and 
Prives, 2009). Although such efforts have met with mixed results, exploring new 
avenues in p53 restoration/reactivation does appear to promise therapeutic 
benefit. One such approach to reactivate wild-type p53 is by inhibiting its 
interaction with Mdm2, thereby increasing its half-life and leading to p53 
accumulation within cells. 
MURINE DOUBLE MINUTE 2 HOMOLOG (MDM2) 
The expression of the tumor suppressor protein p53 is maintained at low levels 
within normal unstressed cells (despite constitutive expression of its mRNA); this 
tight regulation of its expression is largely attributable to Mdm2 protein. Originally 
identified as a gene amplified in double minute chromosomes in mouse 
fibroblasts, it is now best characterized as the negative regulator of p53 protein. 
Multiple mechanisms by which Mdm2 regulates p53 expression and function 
have been identified. First, Mdm2 strongly binds p53 at its N-terminal TAD1 sub-
domain and inhibits transcriptional activation function of p53 (Momand et al., 
1992). Second, Mdm2 is a RING-finger ubiquitin ligase with high specificity for 
p53. It targets p53 for ubiquitination and thereby mediates its degradation by the 
26S proteasome (Haupt et al., 1997; Honda et al., 1997; Kubbutat et al., 1997). 
Third, Mdm2 contains a signal sequence that is similar to the nuclear export 
signal of many viral proteins. It can, therefore, bind to p53 and promote its 
nuclear export, hence making p53 inaccessible to targeted DNA for 
transcriptional regulation (Chene, 2003). Furthermore, Mdm2 can also suppress 
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p53 protein translation either by binding directly to p53 mRNA, or by mediating 
degradation of the ribosomal protein RPL26 which has been shown to have an 
obligate role for p53 translation in response to genotoxic stress (Manfredi, 2010). 
On the other hand, Mdm2 gene promoter contains p53 REs, and is 
transcriptionally activated by p53. Mdm2 and p53 are therefore part of an auto-
regulatory feedback loop. 
Human Mdm2 is a protein consisting of 491 amino acids in which four distinct 
regions have been defined. At the N-terminus is the binding site for p53. Central 
part of the protein contains an acidic region and a zinc-finger domain, whereas 
the C-terminus contains a RING finger domain. The middle region of Mdm2 is 
known to interact with a number of proteins, and the C-terminus RING finger is 
also a binding site for a closely related partner, Mdmx (Manfredi, 2010). 
The importance of p53-Mdm2 interaction was demonstrated with homozygous 
deletion of the Mdm2 gene in mice. Their embryos die very early during gestation 
(blastocyst stage), but this phenotype could be rescued with additional deletion of 
the Trp53 gene. This clearly indicates that, during development, regulation of p53 
apoptotic activity by Mdm2 is essential (Jones et al., 1995; Montes de Oca Luna 
et al., 1995). It has also been shown that Mdm2 over-expression blocks p53-
mediated cell cycle arrest and apoptosis (Chen et al., 1996). Many studies have 
described over-expression of Mdm2 in different kinds of tumors. Increased levels 
of Mdm2 can thus confer growth advantage and contribute to tumorigenesis by 
inactivating the p53 pathway in cancers that do possess wild-type p53. Over-
expression of Mdm2 protein can be achieved by amplification of its gene; single 
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nucleotide polymorphism at position 309 (SNP309) in its gene promoter; 
enhanced transcription; or increased translation (Zhao Y, 2013).  
Analysis of over 3000 tumors revealed that Mdm2 gene is amplified in ~7% of 
these tissues; the highest frequency of amplification being observed in soft tumor 
tissues, osteosarcomas, and esophageal carcinomas (Chene, 2003). Mdm2 
amplification and p53 mutations were found to be mutually exclusive. Over-
expression of Mdm2 in human tumors correlates with poor clinical prognosis and 
poor treatment response to current therapeutics (Zhao Y, 2013). Animal 
experiments have revealed that targeted expression of Mdm2 in the mouse leads 
to increased tumorigenesis. Likewise, in mouse models of cancer in which p53 
inactivation is known to play a role, evidence suggests that this can also occur 
through enhanced expression of Mdm2 (Manfredi, 2010). 
A variety of stress signals disrupt the p53-Mdm2 interaction, thus leading to p53 
accumulation/activation, and setting into motion downstream p53 effector 
pathway(s). Disruption of p53-Mdm2 interaction can be achieved by two means 
(Zilfou and Lowe, 2009): 
a) By post-translational modifications (mainly phosphorylation) of multiple 
residues in the NH2-terminus of p53 protein by various kinases including 
ATM, ATR, DNA-PK, Chk1, Chk2 in response to DNA damage from IR or 
chemotherapeutic agents. Such post-translational events inhibit the ability 
of Mdm2 to ubiquitinate and degrade p53, thereby stabilizing its 
expression. 
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b) P53-Mdm2 interaction is also antagonized by negative regulation of Mdm2 
mediated by p14ARF (p19ARF in mouse) in response to oncogenic 
challenges, resulting in p53 protein stabilization. Notably, p14ARF binds to 
Mdm2 at a site distinct from p53-Mdm2 interface, and therefore is not a 
competitive inhibitor (Eischen et al., 1999; Palmero et al., 1998). 
Recent evidence also suggests that mere disruption of p53-Mdm2 interaction 
using chemical inhibitors, even in the absence of phosphorylation on key p53 
residues, is sufficient for p53 to act as a transcriptional regulator (Thompson et 
al., 2004; Vassilev et al., 2004). Likewise, ablation of Mdm2 levels using RNAi 
approaches resulted in p53-dependent transcriptional activity in the absence of 
either phosphorylation or acetylation on specific relevant sites (Giono and 
Manfredi, 2007). 
Like p53, Mdm2 protein is subject to regulation by post-translational 
modifications such as phosphorylation and acetylation. Various phosphorylation 
sites on Mdm2 have been identified, and based on the site and the kinase 
involved, these modifications can inhibit or enhance Mdm2 activity. ATM and c-
Abl kinases inhibit Mdm2 activity by inducing phosphorylation of Serine 395 
(S395) and Tyrosine 394 respectively. CBP/p300-mediated acetylation of Mdm2 
also exerts an inhibitory effect on its activity (Kruse and Gu, 2009). Such 
modifications lead to p53 accumulation and activation of p53-regulated 
pathways. Conversely, phosphorylation of Mdm2 at positions S166 and S186 by 
the cell survival kinase Akt/PKB not only enhances its E3 ligase activity but also 
promotes its nuclear entry, and facilitates the export of p53 from the nucleus to 
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the cytoplasm, leading to increased degradation of p53 and significant inhibition 
of p53-mediated apoptosis (Limesand et al., 2006; Mayo and Donner, 2001). 
PROSTATE APOPTOSIS RESPONSE- 4 (PAR-4) 
Identification of Par-4: 
The prostate apoptosis response-4 (Par-4) gene was first identified by differential 
hybridization technique as an immediate early apoptotic gene induced in 
response to elevated intracellular Ca2+ concentration ([Ca2+]i) in androgen-
independent rat prostate cancer cell line, AT-3, treated with Ionomycin. Par-4 
expression was also observed in apoptotic androgen-dependent rat ventral 
prostate following castration. Furthermore, Par-4 gene induction was not 
observed in liver, kidneys or other androgen receptor containing organs which do 
not undergo apoptosis upon castration. This observation, combined with the fact 
that Par-4 expression occurs only downstream to apoptotic signaling, and not in 
other processes such as growth stimulation, necrosis, oxidative stress or growth 
arrest established Par-4 as an apoptosis-specific gene (Sells et al., 1994). 
Human Par-4, which was found to share significant sequence homology with its 
rat counterpart, was subsequently identified in yeast-two hybrid studies as a 
partner of the tumor suppressor Wilm’s tumor1 (WT1) (Johnstone et al., 1996) 
and atypical Protein Kinase C (aPKC) (Diaz-Meco et al., 1996). Ubiquitous Par-4 
expression has also been observed in nearly all tissues of mice, horses, pigs, 
and cows. In addition, Par-4 is also known to be expressed in other vertebrates 
such as fish, birds, and Xenopus (El-Guendy and Rangnekar, 2003). Constitutive 
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expression of Par-4 is seen in virtually all tissues of ectodermal, mesodermal, 
and endodermal origin (Boghaert et al., 1997).  
Following the discovery of Par-4 and its pro-apoptotic functions, the majority of 
studies revolved around its role as an intracellular protein. However, a seminal 
study by Burikhanov et al. showed that Par-4 is secreted by almost all types of 
cells, and is available in systemic circulation. Secretion of Par-4 was shown to 
occur independently of apoptosis, and through the classical secretory pathway 
involving the endoplasmic reticulum (ER) and the golgi network. Secreted Par-4 
is known to retain its pro-apoptotic potential and is able to selectively target 
cancer cells when applied extracellularly (Burikhanov et al., 2009). Research 
over the years has established Par-4 as a cancer cell-selective pro-apoptotic 
protein, and a bona fide tumor suppressor. 
Structure  
Human Par-4 gene has been mapped to the minus strand of chromosome 12q21 
(Johnstone et al., 1998). The gene comprises seven exons and six introns, and a 
total of 99.06 kb of DNA (Zhao and Rangnekar, 2008). Par-4 is known to be 
evolutionarily conserved among all vertebrates (Boghaert et al., 1997). The 
product of the Par-4 gene is an approximately 38 kDa protein consisting of 342 
amino acids in humans; 332 amino acids in rats; and 333 amino acids in mice. 
Rat and mouse Par-4 proteins exhibit a 93% amino acid homology, and rat and 
human Par-4 proteins possess about 75% identical and 84% functionally similar 
amino acids. Moreover, the protein domains that are presumably of high 
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functional importance are 100% conserved across these three species (El-
Guendy and Rangnekar, 2003). 
Some of the conserved functional domains of Par-4 are: a) two putative nuclear 
localization sequences (NLS) designated NLS1 (amino acid residues 20-25) and 
NLS2 (a bipartite sequence comprising residues 137-153) in the N-terminal 
region, b) a nuclear export sequence (NES) in the C-terminus, and c) a leucine-
zipper domain spanning amino acids 290-332 in the C-terminal region (El-
Guendy and Rangnekar, 2003). Both NLS1 and NLS2 are conserved across the 
human, mouse and rat species. However, studies using deletion mutants of Par-
4 have shown that only NLS2 is required for translocation of Par-4 into the 
nucleus and subsequent induction of apoptosis. The leucine zipper domain at the 
C-terminus of Par-4 is not required for its apoptotic function. Considering the role 
of this domain in various protein-protein interactions, the leucine zipper appears 
more important for the regulation of Par-4 function by partner proteins such as 
WT-1, PKCζ, Akt1 etc (El-Guendy et al., 2003). Par-4 also contains in its 
sequence several consensus sites for post-translational modifications. 
Phosphorylation of Par-4 by protein kinase A- I (PKA- I) at the Threonine 155 
(T155) residue is known to activate Par-4, and this step is required for Par-4 
function (Gurumurthy et al., 2005). Conversely, phosphorylation of Serine 249 
(S249) by the Akt1/PKB Serine/threonine (S/T) kinase has been shown to 
inactivate Par-4 by subjecting it to 14-3-3-mediated sequestration in the 
cytoplasm (Goswami et al., 2005). Par-4 also possesses a putative ATP/GTP-
binding domain, and several consensus sites for phosphorylation by kinases 
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such as protein kinase C (PKC) and casein kinase 2 (CK2), although their 
functional importance remains to be investigated (Hebbar et al., 2012). 
Selective for Apoptosis in Cancer Cells (SAC) Domain 
Analysis of several mutants resulting from serial deletion of the full-length Par-4 
protein from both the amino and carboxy termini led to the identification of a 
unique core domain, spanning amino acids 137-195, that is sufficient to carry out 
the apoptotic function of Par-4. It was observed that this 58-amino acid fragment 
of Par-4, when over-expressed, induces apoptosis specifically in cancer cells 
only, and therefore is called the ‘selective for apoptosis of cancer cells’ (SAC) 
domain. The SAC domain is 100% conserved among mammals (including 
rodents, humans and chimpanzee), chicken, frog and zebra fish. This segment 
contains the NLS2, which facilitates its nuclear translocation, and the PKA 
phosphorylation site, T155, which is responsible for its activation, but excludes 
the C-terminal leucine zipper domain. It is interesting to note that the SAC 
domain shows nuclear localization, and is capable of inducing apoptosis not only 
in Par-4 sensitive cancer cells, such as PC3, DU145, LNCaP/IL-6, but also in the 
cells that show primarily cytoplasmic localization of full-length Par-4, and are 
resistant to its apoptotic actions, such as LNCaP, MCF-7 etc. However, neither 
Par-4 nor the SAC domain causes apoptosis in normal cells (El-Guendy et al., 
2003).  
Par-4 is a tumor suppressor 
Evidence from numerous studies across a variety of human cancers, as well as 
experiments in knock-out and transgenic mouse models, has validated Par-4 as 
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a bona fide tumor suppressor. Pancreatic and gastric cancers frequently show a 
deletion or instability in chromosome 12q21, the region where Par-4 is located 
(Kimura et al., 1998; Schneider et al., 2003). It is also possible that aberrant 
expression of this region contributes to Wilm’s tumorigenesis (Johnstone et al., 
1998). Par-4 is observed to be down-regulated in over 70% of renal cell 
carcinoma (Cook et al., 1999); in neuroblastoma (Kogel et al., 2001); endometrial 
cancer (Moreno-Bueno et al., 2007); pancreatic cancer (Ahmed et al., 2008); 
breast cancer (Mendez-Lopez et al., 2010; Zapata-Benavides et al., 2009); 
cholangiocarcinoma (Franchitto et al., 2010); and in high-grade glioblastoma (Liu 
et al., 2014b). In prostate cancer, Par-4 is not down-regulated or mutated, but 
inactivated by Akt-mediated phosphorylation and subsequent sequestration in 
the cytoplasm by chaperone protein 14-3-3 (Goswami et al., 2005). 
In about 32% of the endometrial carcinomas, diminished Par-4 expression was 
observed to be due to promoter hypermethylation. A strong correlation was also 
reported between low Par-4 levels and microsatellite instability in these tumors. 
In addition, Par-4 promoter hypermethylation and silencing could also be 
detected in endometrial cancer cell lines SKUT1B and AN3CA. A single base 
mutation in exon 3 of the Par-4 gene, converting an Arginine residue (CGA) to a 
Stop codon (TGA) thus resulting in a truncated protein, has also been identified 
in endometrial cancer (Moreno-Bueno et al., 2007). In the case of breast cancer, 
emerging data have implicated Par-4 down-regulation as a prognostic factor for 
poor disease outcome and decreased overall survival (Mendez-Lopez et al., 
2010; Nagai et al., 2010). A recent study also identified low Par-4 expression as 
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an independent predictor of reduced recurrence-free survival, and demonstrated 
that down-regulation of Par-4 is necessary and sufficient to promote breast 
cancer recurrence (Alvarez et al., 2013). 
K-Ras mutations are the most frequent mutations in pancreatic cancer, and Par-4 
is reported to be significantly down-regulated in pancreatic cancers harboring K-
Ras mutations. Tumors with such K-ras mutations tend to be highly aggressive 
and therapy-resistant, whereas tumors with higher Par-4 levels have better 
prognosis (Ahmed et al., 2008). Oncogenic Ras is known to down-regulate Par-4 
in a variety of cells via the MEK-ERK pathway, and this is considered to be an 
important step towards Ras-induced transformation. Restoration of Par-4 levels 
either by the MEK inhibition or by stable expression of ectopic Par-4 abrogates 
cellular transformation (Barradas et al., 1999; Pruitt et al., 2005; Qiu et al., 1999). 
Furthermore, in Ras-transformed epithelial cells, long-term decrease in Par-4 
expression has been demonstrated to be achieved by MEK-dependent 
hypermethylation of the Par-4 promoter (Pruitt et al., 2005). There is also 
evidence that if Par-4 is reinstated in these cells by transient transfection, it will 
selectively sensitize the cells expressing oncogenic Ras, but not those that lack 
oncogenic Ras, to apoptosis; and this action of Par-4 is achieved by inhibition of 
NF-κB-mediated transcriptional activation (Nalca et al., 1999). The tumor-
suppressor function of Par-4 has also been demonstrated in hematopoietic stem 
cells where it antagonizes the activation of oncogenic Ras, and disrupts BCR-Abl 
signaling to produce anti-transformation outcomes (Kukoc-Zivojnov et al., 2004). 
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Animal studies have demonstrated that Par-4 knockout mice are prone to 
spontaneous development of tumors in various tissues, e.g. lungs, liver, urinary 
bladder and endometrium, and also exhibit prostatic intraepithelial neoplasia 
(PIN). The study also shows that Par-4 knockout mice are more susceptible to 
chemical- or hormone-induced endometrial and prostatic lesions. Animals 
homozygous for Par-4 knockout also have a significantly shorter life span 
compared to heterozygous knockout or wild-type animals (Garcia-Cao et al., 
2005).  
In contrast, transgenic mice over-expressing full-length Par-4 or the SAC domain 
of Par-4 show remarkable protection against the growth of spontaneous or 
oncogene-induced autochthonous tumors. Interestingly, when SAC transgene 
was co-expressed with oncogenic SV40 antigens in mice, normal or benign 
prostatic epithelial cells continued to express SAC, whereas all prostate intra-
epithelial neoplasia (PIN) and adenocarcinoma lesions showed down-regulation 
or elimination of the SAC transgene, indicating that loss of SAC is a pre-requisite 
for progression into malignant disease (Zhao et al., 2007). A similar observation 
was recently made when Alvarez et. al. noted that endogenous, and even 
ectopically expressed Par-4 was lost from recurrent breast tumors in their study 
with mouse models (Alvarez et al., 2013). In addition, studies with transgenic 
mouse models indicate that mice that express systemic Par-4/SAC protein are 
resistant to the growth of non-autochthonous tumors. Importantly, transplantation 
of bone marrow from cancer-resistant transgenic mice to cancer-susceptible wild-
type mice conferred cancer resistance, further confirming the potent anti-tumor 
 
32 
 
activity displayed by secretory Par-4/SAC. Moreover, intravenous injection of 
recombinant Par-4 or SAC protein could effectively inhibit lung metastasis of 
Lewis Lung Carcinoma (LLC 1) cells (Zhao et al., 2011). Overall, these results 
reiterate the cancer cell-specific apoptotic action and tumor-suppressive role of 
Par-4. 
Par-4 and apoptosis 
The pro-apoptotic action of Par-4 is indicated by its increased expression in 
actively apoptosing cells, e.g. the granulosa cells of atretic ovarian follicles; 
interdigitating web cells of the mouse embryo; involuting tadpole tail; and dying 
neurons during neuronal development, wherein apoptosis induced in the neurons 
serves to maintain the number of neurons in the nervous system (El-Guendy and 
Rangnekar, 2003). The fact that the prostatic ductal cells do not normally express 
Par-4, but when subjected to testosterone ablation by castration, these 
apoptosing cells do express Par-4 further underscores the pro-apoptotic function 
of Par-4 (Boghaert et al., 1997). 
Studies conducted in cell culture models show that over-expression of Par-4 is 
sufficient to directly induce apoptosis in most cancer cells, and this apoptotic 
action of Par-4 can override cell-protective mechanisms, such as presence of 
Bcl-2, Bcl-xL or absence of wild-type p53 or PTEN function. In contrast, over-
expression of Par-4 does not induce apoptosis in normal or immortalized but 
non-transformed cells, but only serves to  sensitize such “resistant” cells to 
additional apoptotic signal(s), such as increased intracellular Calcium (Ca2+), 
growth factor withdrawal, Tumor Necrosis Factor- α (TNF-α), or ultraviolet (UV), 
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X-ray and gamma radiation (Chakraborty et al., 2001; El-Guendy et al., 2003; 
Nalca et al., 1999). Similar to Par-4, SAC domain causes apoptosis in a wide 
variety of cancer cells while leaving the normal cells unharmed (El-Guendy et al., 
2003).   
The cancer cell-specific apoptotic effect of Par-4 is evident in vivo as well. A 
single injection of adenoviral construct of Par-4 into solid subcutaneous tumors 
produced in mice by implanting PC-3 cells resulted in a drastic reduction in tumor 
volume within 3 weeks. This outcome was largely due to an increase in apoptosis 
caused by Par-4 (Chakraborty et al., 2001). Similarly, in tumors generated by 
xenotransplanted A375-C6 melanoma cells in SCID mice, over-expression of 
Par-4 correlated with decreased tumor development, and an increase in 
apoptosis (Lucas et al., 2001). The Par-4/SAC transgenic mice are 
physiologically and developmentally normal when scored in terms of fertility, 
gender ratio, viability, body weight and aging characteristics, but show 
remarkable resistance to the growth of spontaneous as well as induced tumors, 
which further underscores the fact that Par-4 induces apoptosis specifically in 
cancer cells, while normal cells are largely unaffected (Zhao et al., 2007). 
A number of studies in cell culture models have described the role of Par-4 in 
sensitizing different cell types to the apoptotic effects of various stimuli, such as 
growth factor withdrawal, TNF- α, UV, X-ray and gamma radiation (Chakraborty 
et al., 2001; Chendil et al., 2002; El-Guendy and Rangnekar, 2003; Nalca et al., 
1999). Par-4 is also considered to be an essential down-stream regulator of the 
apoptotic actions of a wide variety of chemical/physical therapeutic agents such 
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as Vincristine, TNF-related apoptosis inducing ligand (TRAIL), Adriamycin, and 
Ionizing Radiation (IR) (Gurumurthy et al., 2005; Ranganathan and Rangnekar, 
2005). Diminished expression of Par-4 has often been linked with reduced 
sensitivity to apoptosis in response to treatment with therapeutic agents. Par-4 is 
down-regulated in many cancers, and reduced levels or loss of Par-4 has been 
shown to confer increased resistance of cancer cells to chemotherapeutic agents 
such as Adriamycin, Etoposide, Vincristine, Cisplatin and 5-Fluorouracil (5-FU) 
(Affar el et al., 2006; Alvarez et al., 2013; Tan et al., 2014; Wang et al., 2010). In 
a recent study, extensive analysis of patient datasets revealed that breast tumors 
with the poorest response to neo-adjuvant chemotherapy (represented by the 
greatest amount of residual cancer burden) exhibited substantially lower 
expression of Par-4 prior to therapy than tumors that showed a better response 
to chemotherapy. Using clinically relevant mouse models, the same study 
showed that breast cancer cells with reduced Par-4 expression could survive 
apoptosis caused by oncogene inhibition and by treatment with 
chemotherapeutic agents, and that this therapy-resistant population later on 
emerges as recurrent tumor (Alvarez et al., 2013). 
Mechanisms of apoptosis by Par-4 
The apoptotic effect due to Par-4 involves either an activation of the cellular 
apoptotic machinery or inhibition of the cellular pro-survival mechanisms. Par-4 
induces apoptosis in cancer cells by enabling the translocation of Fas and Fas 
ligand (FasL) to the plasma membrane. Fas receptor belongs to the TNF-
receptor (TNFR) family of type-I transmembrane proteins that possess a 
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conserved intracellular C-terminal ‘death domain’. Activation of Fas receptor, for 
example by binding to FasL, triggers trimerization of the receptor, and recruits 
the adapter protein FADD, thereby initiating the formation of DISC and 
unleashing the caspase cascade. Therefore, in these cells, over-expression of 
Par-4 is a sufficient signal for cell death (Chakraborty et al., 2001). 
In parallel, Par-4 also translocates into the nucleus and inhibits NFκB-mediated 
cell survival mechanisms; and this inhibition constitutes one of the essential 
mechanisms of Par-4-induced apoptosis (Nalca et al., 1999). NFκB regulates a 
number of pro-survival genes, including but not limited to, cell-protective genes 
such as those of the Bcl-2 family, e.g. Bcl-xL, Al/Bfl1; and anti-apoptotic genes 
such as X-linked inhibitor of apoptosis (XIAP) that can protect the cell from TNF-
induced apoptosis (Barkett and Gilmore, 1999). Activation of Par-4 by PKA-
dependent phosphorylation at T155 is considered to be critical for both Fas/FasL 
translocation and NF-κB inhibition (Gurumurthy et al., 2005). In other studies, 
Par-4 has been shown to function in the cytoplasm, wherein it represses NFκB-
dependent gene transcription by inhibiting the TNFα-induced nuclear 
translocation of p65 (Rel A) subunit by blocking the aPKC- or IKKβ-mediated 
phosphorylation of IκB, and this mechanism occurs without disrupting DNA-
binding capability of the NFκB complex (Diaz-Meco et al., 1999). A novel 
mechanism for Par-4-induced apoptosis in breast cancer was recently described. 
In response to oncogene inhibition or treatment with chemotherapeutic agents, 
Par-4 was observed to induce ZIP-kinase-dependent phosphorylation of Myosin 
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Light Chain 2 (MLC2), resulting in multinucleation, and ultimately apoptosis due 
to cytokinesis failure (Alvarez et al., 2013).  
Apoptotic action of extracellular or secreted Par-4 is known to be mediated by 
Glucose Regulated Protein 78 (GRP78), which acts as a receptor for Par-4 at the 
cell surface. Par-4 is known to bind the N-terminal region of GRP78 via its SAC 
domain, and this ligation results in the initiation of a robust feedback loop which 
involves the trafficking of more GRP78 to cell surface in a Par-4 dependent 
manner. The binding of Par-4 to GRP78 results in elevated ER stress and, 
therefore, activation of the ER stress response protein PERK (PKR-like ER 
kinase), which in turn leads to the activation of caspase-8 and caspase-3 through 
a FADD dependent mechanism. The cancer-specific activity of secreted Par-4 is 
due to differential expression of GRP78 in cancer and normal cells. GRP78 is 
found almost exclusively on the surface of cancer cells, and this accounts for the 
susceptibility of cancer cells to the apoptotic action of secreted Par-4 (Burikhanov 
et al., 2009). Intracellularly, cancer cell specificity of Par-4 may also be due to 
enhanced PKA-mediated phosphorylation of T155 residue in Par-4/SAC domain 
as a result of elevated expression and/or activity of the enzyme PKA1 in cancer 
cells and primary tumors compared with normal cells (Gurumurthy et al., 2005).  
Project objectives 
Research from our lab has shown that the tumor suppressor Par-4 is secreted, 
and induces apoptosis specifically in cancer cells. Such cancer cell selectivity 
exhibited by extracellular Par-4 is a much desired characteristic which can be 
harnessed and exploited to conceptualize novel effective therapeutic strategies. 
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The aim of this dissertation project work is to identify means to enhance Par-4 
secretion and elevate its systemic levels so as to eliminate remote tumor cells 
(chapter 2). Secondly, this dissertation work also investigates the mechanism(s) 
related to apoptosis resistance engendered by Par-4 loss or down-regulation 
using cells derived from Par-4+/+ (wild-type) or Par-4-null background (chapter 3). 
Chapter 2: Par-4 mediates paracrine apoptotic effect of p53 
1. To identify molecular regulator(s) of Par-4 secretion. 
2. To identify mechanism by which Par-4 secretion is regulated by the said 
molecular regulator. 
3. To determine if small molecules can be used to modulate Par-4 secretion 
and cause apoptosis of cancer cells in a paracrine manner. 
Chapter 3:  
1. To determine the effect of Par-4 loss on apoptosis caused by different 
agents using primary fibroblasts differing only in Par-4 status. 
2. To investigate the mechanisms pertaining to apoptosis resistance 
engendered by Par-4 loss. 
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Figure 1.1: Intrinsic and extrinsic pathways apoptotic pathways 
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Figure 1.1: Intrinsic and extrinsic pathways apoptotic pathways. Apoptosis 
can be initiated by activation of two distinct, albeit ultimately converging, 
pathways, the “Bcl-2-regulated pathway” (left; also known as the “stress” or 
“mitochondrial” or “intrinsic” pathway) and the “death receptor pathway”, also 
known as the “extrinsic pathway” (right). Protein–protein interactions between 
members of the Bcl-2 family govern activation of the Bcl-2-regulated pathway, 
whereas binding of their cognate ligands activates the death receptors (e.g., 
FAS, TNF-R1). Intrinsic pathway leads to the activation of Caspase 9, whereas 
extrinsic pathway activates Caspase 8. Cellular demolition is performed by the 
effector caspases 3, 6, and 7 that act downstream of both pathways. 
Figure adapted from Delbridge et. al. Cold Spring Harb Perspect Biol. 2012 Nov 
1;4(11). 
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Figure 1.2: Domain structure of p53 
 
 
 
Figure 1.2: Domain structure of p53. p53 contains a natively unfolded amino-
terminal transactivation domain (TAD), which can be further subdivided into the 
subdomains TAD1 and TAD2, followed by a proline-rich region (PRR). The 
structured DNA-binding and tetramerization domains (OD) are connected 
through a flexible linker region. Similarly to the TAD region, the regulatory 
domain at the extreme carboxyl terminus (CTD) is also intrinsically disordered. 
The vertical bars indicate “hot-spots” for relative missense-mutation frequency in 
human cancer.  
Figure adapted from Joerger and Fersht, Cold Spring Harb Perspect Biol. 2010 
Jun;2(6). 
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Figure 1.3: P53 effector pathways in mediating tumor suppression 
 
 
Figure 1.3: P53 effector pathways in mediating tumor suppression. The p53 
effector functions of cell cycle arrest, senescence, apoptosis, autophagy, and 
metabolism regulation are co-ordinated by a number of p53 target genes. These 
genes are turned on depending on the type and extent of stimulus received; cell 
type; and general physiological context. These effector functions of p53 are 
critical in p53-mediated tumor suppression. 
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Figure 1.4: Domain structure of human Par-4 
 
 
Figure 1.4: Domain structure of human Par-4. The best characterized 
conserved domains of Par-4, namely, the N-terminal Nuclear Localization 
Sequences 1 and 2 (NLS1 and NLS2), Selective for Apoptosis of Cancer Cells 
(SAC), and the C-terminal Leucine Zipper (LZ) domains are illustrated. Activation 
by PKA-mediated phosphorylation at T163 is essential for Par-4 function. 
Conversely, Par-4 is inactivated by Akt-mediated phosphorylation at S230. 
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Figure 1.5: Apoptosis by intracellular and extracellular Par-4 
 
Figure 1.5: Apoptosis by intracellular and extracellular Par-4. Apoptosis 
induction by Par-4 involves membrane translocation of death receptors of the 
CD95 family (Fas/FasL). Ligation of Fas with FasL recruits FADD, an adapter 
protein with cytoplasmic death domain, which in turn serves to recruit procaspase 
8 molecules and initiate the proteolytic caspase cascade. Par-4-mediated 
apoptosis also involved inhibition of NF-κB-mediated pro-survival pathways. 
Extracellular Par-4 interacts with its receptor GRP78 and drives membrane 
recruitment of FADD, thus initiating the extrinsic pathway for apoptosis.
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CHAPTER TWO: PAR-4 MEDIATES PARACRINE APOPTOTIC EFFECT OF P53 
 
INTRODUCTION 
Lung cancer is the leading cause of cancer deaths in both men and women in the 
United States (Siegel et al., 2014). Activation of the Ras oncogene and loss of 
tumor suppressor p53 are the two most commonly occurring alterations in lung 
cancer (Wang et al., 2006). An intact p53 signaling pathway is believed to be 
essential for growth arrest and cell death caused by diverse chemotherapeutic 
agents and ionizing radiation. Conversely, loss of p53 function in the tumors may 
confer therapeutic resistance, ultimately leading to death of the patients (Chen et 
al., 2010; Levine, 1997; Sekido, 2001). P53 knock-out or p53-mutant mice 
develop spontaneous, as well as inducible tumors (Donehower et al., 1995; 
Donehower et al., 1992; Jacks et al., 1994) while p53 transgenic mice exhibit 
tumor-free survival with an increased life span (Garcia-Cao et al., 2002; Matheu 
et al., 2007). As up- or down-regulation of transcriptional target genes involved in 
cell cycle progression or apoptosis plays an important role in the tumor 
suppressor function of p53, it is not surprising that p53 is mutated within its DNA 
binding domain in a large number of human cancers (Petitjean et al., 2007). 
Given the role of p53- as the “guardian of the genome”- in controlling diverse 
cellular processes that contribute towards preventing oncogenic transformation, it 
is perhaps not surprising that a major part of p53 research has focused on its 
cell-autonomous functions. However, in the recent years, with increasing interest 
in the role of tumor microenvironment, we can also find a growing body of 
evidence suggesting a non cell-autonomous role for p53, whereby p53 function in 
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the stromal compartment can be instrumental in tumor inhibition. Kiaris et. al. 
observed reduced latency in tumor development in p53-null mice relative to wild-
type mice, indicating that p53 activity in the host may exert an inhibitory effect on 
cancer progression (Kiaris et al., 2005). Several studies have revealed that 
tumor-associated stromal cells also frequently undergo genetic alterations in the 
Tp53 locus manifested by somatic mutations and loss of heterozygosity (LOH), 
similar to those observed in primary tumors (Kurose et al., 2002; Moinfar et al., 
2000; Paterson et al., 2003; Wernert et al., 2001). Moreover, tumor progression 
imposes a strong selective pressure for loss of p53 function in cancer-associated 
fibroblasts (Addadi et al., 2010; Hill et al., 2005).  
These observations support the view that p53 function in both normal and cancer 
compartments of the tumor is important for suppression of tumor progression. 
However, the precise mechanism by which p53 loss in normal or stromal cells 
may contribute to tumor progression is not well understood.  Because normal 
cells in the body of the patient except in the tumor micro-environment are 
expected to express wild type p53, we determined whether activation of p53 
function in normal cells causes paracrine growth inhibitory effects in cancer cells. 
Specifically, we asked whether p53 activation in normal cells induces the 
secretion of pro-apoptotic proteins systemically and whether such proteins act to 
inhibit the growth of p53-deficient tumor cells in a paracrine manner. Our findings 
indicate that activation of p53 in normal cells promotes the secretion of Prostate 
apoptosis response-4 (Par-4), a pro-apoptotic tumor suppressor protein 
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(Burikhanov et al., 2009). Importantly, secreted Par-4 mediates a paracrine 
growth-inhibitory effect by inducing apoptosis of p53-deficient cancer cells. 
 
MATERIALS AND METHODS 
 
Cells, plasmids, and chemical reagents 
Lung cancer cells H1299, HOP92, prostate cancer cells PC-3, and primary lung 
fibroblast cells HEL were from ATCC, MD. IKKβ+/+ and IKKβ-/- MEFs were 
previously described (Burikhanov et al., 2013). Par-4+/+ and Par-4-/- MEFs were 
derived from wild type and Par-4-null C57/B6 mice (Figure 2.5).  P53+/+ and p53-/- 
MEFs in the 3rd passage were from Tyler Jacks (MIT, MA). Nutlin-3a was from 
Cayman Chemicals, and PS-1145, z-VAD-fmk and BFA were from Sigma 
Chemicals. UACA constructs were described previously (Burikhanov et al., 
2013). The p53 constructs were from Wafik El-Deiry (Penn State University, PA).  
Immortalized Balb/c fibroblasts (10)1, with no endogenous p53, and (10.1)Val5 
cell line derived from 10(1) cells by stable transfection with the temperature-
sensitive p53 allele encoding Valine at 135aa, were from Arnold Levine (Institute 
for Advanced Study, NJ). The p53 mutant in (10.1)Val5 cells exhibits wild type 
conformation at 32 °C, judged by p21/WAF1 induction, and mutant conformation 
at 37-39 °C (Harvey and Levine, 1991; Wu and Levine, 1994).  
Generation of Par-4/Pawr knock out mice 
Par-4 knock out (KO) mice were generated using the C57/B6 mouse 
background. As Exon 2 contains the initiating ATG codon, it was flanked by loxP 
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sites. The selection marker (Neomycin, Neo) was flanked by FRT sites and 
introduced into intron 2. Constitutive knock out allele was generated after in vivo 
Cre-mediated recombination that resulted in deletion of Exon 2 and loss of Par-4 
function, owing to removal of the initiating ATG codon. Par-4+/- mice were 
intercrossed to generate Par-4-/- mice. Par-4 null mice grow normally and develop 
spontaneous tumors in diverse tissues as previously reported (Moreno-Bueno et 
al., 2007). MEFs isolated from the Par-4-/- mice and corresponding Par-4+/+ 
littermate control mice were studied for Par-4 secretion (Figure 2.5). 
Co-immunoprecipitation and Western blot analysis 
Protein extracted from cell lysates was filtered, pre-cleared with 25 µl (bed 
volume) of protein G-Sepharose beads and immunoprecipitated with 1 µg of 
respective antibodies. The eluted proteins were resolved by SDS-PAGE, and 
subjected to Western blot analysis as described (Goswami et al., 2008).  
Antibodies and siRNA duplexes 
The polyclonal antibody for UACA was from Bethyl Laboratories. Par-4 (R332), 
Col1A1 (H-197), pan-cytokeratin (C11), p53 (FL-393), p21/WAF1 (F5), and rabbit 
IgG antibodies were from Santa Cruz Biotechnology, Inc. The mouse monoclonal 
antibody for p53 (1C12 mAb), cleaved caspase 3 antibodies were from Cell 
Signaling, and that for β-actin was from Sigma Chemical Corp. The control 
siRNA and pools of siRNA for UACA were from Dharmacon and SantaCruz 
Biotechnology, Inc. 
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Quantitative Real Time-PCR analysis 
Approximately 1x106 cells were infected with GFP control or GFP-tagged p53-
adenovirus for 24 hours, and total RNA was extracted using Trizol reagent. 
Quantitative Real Time-PCR (qRT-PCR) was performed using SuperScript First-
Strand Synthesis System (Invitrogen) using oligo (dT) primers for RT. Brilliant II 
SYBR Green Master Mix (Agilent Technologies) was used for subsequent qPCR. 
Primers used for qPCR were as follows:  
18S RNA  
Forward primer: 5’-cgc cc tag agg tga aat tct-3’  
Reverse primer: 5’-cga acc tcc gac ttt cgt tct-3’ 
Human UACA  
Forward primer: 5’-ggc gga gaa cga taa gtt gac taa-3’  
Reverse primer: 5’-cat gtt tct cgg gag cta caa ac-3’ 
Reverse transcriptase-PCR analysis 
For the reverse-transcriptase PCR experiment with co-transfection, 
approximately 1.5x106 IKKβ-/- cells were co-transfected with either vector, wild-
type(wt) UACA, or mutant(m) UACA construct with or without p53 plasmid for 72 
hours, and total RNA was extracted using RNeasy mini kit (Qiagen). Reverse 
transcription was performed to synthesize cDNA with random hexamers using 
SuperScript III First-Strand Synthesis System (Invitrogen), and was followed by 
PCR. PCR products were then subjected to DNA gel electrophoresis. Primers 
used were as follows:  
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18S RNA  
Forward primer: 5’- gta acc cgt tga acc cca tt -3’  
Reverse primer: 5’- cca tcc aat cgg tag tag cg -3’  
pCB6+ human UACA wild type or mutant constructs  
Forward primer: 5’-aag agc ctc aag tcc cgc c -3’  
Reverse primer: 5’- ccc ccc ttt ctg ctg ctt-3’  
ChIP analysis 
ChIP assays for endogenous p53 binding to the consensus binding site in UACA 
were performed by treating 2x106 HEL cells with either DMSO vehicle or with 
Nutlin-3a for 24 h, and 1x106 cells were used per ChIP reaction in each treatment 
group. Alternatively, for ChIP analysis with ectopic p53 expression, 1x106 cells 
infected with either GFP control or GFP-tagged p53-adenovirus were used per 
ChIP assay.ChIP analysis was performed using the ChIP kit from Millipore 
according to the instructions provided by the manufacturer. Briefly, the proteins 
and DNA were cross-linked with 1% formaldehyde, lysed, and the DNA was 
sheared into 200-800 bp fragments. Proteins linked to the DNA were 
immunoprecipitated with appropriate antibodies (using rabbit IgG or no antibody 
as control). Subsequently, immune complexes were eluted from the beads, 
protein-DNA crosslinks were reversed, and DNA was isolated after 
phenol/chloroform/isoamyl alcohol extraction followed by ethanol precipitation. 
DNA fragments were amplified by PCR using the following primers.  
UACA:  
Forward primer 5’-gtc tac tcc ttg cgc gct gg-3’  
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Reverse primer 5’-gcg gcg cca gac gac-3’.   
p21:  
Forward primer 5’-ctg gac tgg gca ctc ttg tc- 3’  
Reverse primer 5’-ctc cta cca tcc cct tcc tc- 3’ 
GAPDH:  
Forward primer 5’ – atg gtt gcc act ggg gat ct- 3’  
Reverse primer 5’ – tgc caa agc cta ggg gaa ga- 3’ 
Apoptosis assays 
Apoptotic nuclei were identified by immunocytochemical (ICC) analysis for active 
caspase-3, or by 4, 6-diamidino-2-phenylindole (DAPI) staining. A total of three 
independent experiments were performed; and approximately 500 cells were 
scored in each experiment for apoptosis under a fluorescent microscope. 
Animal experiments 
Whole-blood samples and various tissues were collected from mice, 24 h after 
injection via the intra-peritoneal (i.p.) route with Nutlin-3a plus PS-1145 (10mg/kg 
and 5mg/kg body weight, respectively) or corn oil (100 µl) as vehicle control. 
Serum was separated from the blood samples and used for testing. All animal 
procedures were performed with IACUC approval. 
Statistical analysis 
All experiments were performed in triplicate to verify the reproducibility of the 
findings.  Statistical analyses were carried out with Statistical Analysis System 
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software (SAS Institute, Cary, NC) and P values were calculated using the 
Student t test unless otherwise mentioned. 
 
RESULTS 
 
Normal fibroblasts secrete Par-4 protein in a p53-dependent manner.  
To examine whether p53 activation in normal cells exhibits paracrine effects in 
cancer cells, we used co-cultures of mouse embryonic fibroblasts (MEFs) from 
p53+/+ or p53-/- mice with p53-null H1299 and PC-3 cells and p53-mutant HOP92 
cells. The cell cultures were treated with Nutlin-3a, a specific activator of p53 
(Vassilev et al., 2004). Nutlin-3a induced apoptosis in p53-deficient cancer cells 
that were co-cultured with p53+/+ MEFs but not with p53-/- MEFs (Figure 2.1A, left 
panel). As expected, the p53-deficient cancer cells and the MEFs were resistant 
to apoptosis by Nutlin-3a when cultured individually (Figure 2.1A, right panel). 
Because p53 may function by partial inhibition of NF-κB activity (Dey et al., 
2007), we combined Nutlin-3a with PS-1145, a small molecule that specifically 
inhibits IKKβ (Hideshima et al., 2002). By itself, PS-1145 does not induce 
apoptosis of normal or lung cancer cells [Figure 1A, right panel; and (Burikhanov 
et al., 2013)]. However, treatment of the co-cultures with PS-1145 induced 
apoptosis in cancer cells, and the combination of Nutlin-3a plus PS-1145 highly 
augmented that effect (Figure 2.1A).  
To determine whether extracellular factors secreted by the MEFs in response to 
Nutlin-3a and/or PS-1145 treatment contributed to apoptosis of the cancer cells, 
the MEFs were treated with these small molecules, and conditioned medium 
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(CM) was transferred to p53-deficient lung cancer cells or normal lung cells. The 
CM from p53+/+ MEFs but not the CM from p53-/- MEFs treated with Nutlin-3a or 
PS-1145 produced apoptosis of H1299 cells. Moreover, the CM from p53+/+ 
MEFs treated with a combination of Nutlin-3a and PS1145 exhibited an additive 
apoptotic effect in H1299 cells. By contrast, the CM from MEFs treated with 
Nutlin-3a and/or PS-1145 did not induce apoptosis in wild-type TP53 primary 
human lung fibroblasts HEL cells (Figure 2.1B, left panel). Similarly, CM from 
HEL cells treated with Nutlin-3a plus PS-1145 induced apoptosis of H1299 and 
HOP92 cells, but not in HEL cells (Figure 2.1B, right panel). These findings 
indicated that Nutlin-3a and PS-1145 may regulate the secretion of cancer-
selective pro-apoptotic factor(s) in a p53-dependent manner.  
We then examined the CM for secreted proteins, especially TRAIL, maspin, 
IGFBP3, and Par-4, which are known to act extracellularly and induce cancer-
specific apoptosis. The CM from p53+/+ MEFs treated with Nutlin-3a or PS-1145 
showed elevated levels of Par-4 protein, and combination of Nutlin-3a plus PS-
1145 additively increased the secretion of Par-4 (Figure 2.1C). None of the other 
proteins showed elevated secretion with Nutlin-3a plus PS-1145 (data not 
shown). By contrast, p53-/- MEFs accumulated Par-4 protein in the lysate, but 
failed to secrete it in response to these treatments (Figure 2.1C). However, 
secretion of Collagen (Col1A1) was unaffected by the treatments in p53+/+ or p53-
/- MEFs, implying that p53-/- MEFs were not generally deficient in protein 
secretion (Figure 2.1C, lower panel). Moreover, pre-treatment of p53+/+ cells with 
pan-caspase inhibitor z-VAD-fmk did not diminish Nutlin-3a plus PS-1145-
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inducible secretion of Par-4 protein, indicating that Par-4 secretion was not a 
post-apoptosis event (Figure 2.1D).  
Importantly, the Par-4 antibody but not the PTEN control antibody inhibited 
apoptotic activity in the CM (Figure 2.1E, left panel), implying that secreted Par-4 
mediates the paracrine apoptotic action of p53. Consistent with these 
observations, the CM from Par-4+/+ MEFs but not Par-4-/- MEFs treated with 
Nutlin-3a plus PS-1145 induced apoptosis of p53-deficient cancer cells (Figure 
2.1E, middle and right panels). Moreover, doxorubicin, which is known to activate 
p53, induced Par-4 secretion from Par-4+/+ but not Par-4-/- MEFs, and the CM 
collected from Par-4+/+ but not Par-4-/- MEFs induced apoptosis of p53-deficient 
cancer cells (Figure 2.1F).  Together, these findings suggested that p53 
regulates the secretion of Par-4 protein, which selectively induces apoptosis in 
cancer cells.  
p53 induces systemic expression of Par-4 in normal mice.   
We examined whether p53 regulates the secretion of Par-4 in vivo. The serum of 
untreated C57/B6 p53+/+ mice contained higher levels of Par-4 relative to p53-/- 
mice (Figure 2.2A, left panel). When p53+/+, p53-/-, and Par-4-/- mice were injected 
with Nutlin-3a plus PS-1145 or vehicle control, and serum samples were 
collected for analysis of Par-4, we noted that relative to vehicle control, Nutlin-3a 
plus PS-1145 caused a ~5-fold increase in serum levels of Par-4 protein in p53+/+ 
mice. By contrast, Nutlin-3a plus PS-1145 failed to elevate systemic levels of 
Par-4 in p53-/- mice or Par-4-/- mice (Figure 2.2A, right panel), implying that p53 
function was essential for up-regulation of Par-4 secretion in mice. Importantly, 
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the serum from Nutlin-3a plus PS-1145 treated p53+/+ mice, but not p53-/- mice or 
Par-4-/- mice, induced ex vivo apoptosis of cancer cell cultures but not normal cell 
cultures (Figure 2.2B, upper panel). By contrast, the serum from vehicle-treated 
mice failed to induce apoptosis over background levels in normal or cancer cells 
(Figure 2.2B, lower panel). Moreover, pre-incubation of the serum samples 
collected from Nutlin-3a plus PS-1145 treated p53+/+ mice with the Par-4 antibody 
but not the PTEN control antibody, significantly inhibited the ability of the serum 
to induce apoptosis of cancer cell cultures (Figure 2.2C). Together, these 
findings suggest that p53 activation in normal mice induces adequate levels of 
systemic Par-4 protein that is functionally effective in inducing apoptosis of 
cancer cells.  
P53 down-regulates the expression of UACA to induce Par-4 secretion.   
As Par-4 does not contain a p53 consensus binding site in its DNA, Par-4 
secretion is likely regulated by another downstream target of p53. To identify the 
primary gene target of p53, we used three criteria: (1) it should encode a protein 
that binds to Par-4, (2) it should be regulated by p53, and (3) it should be induced 
by NF-κB activity. We recently identified UACA (uveal autoantigen with coiled-coil 
domains and ankyrin repeats) as a strong binding partner of Par-4 (Burikhanov et 
al., 2013). UACA was co-immunoprecipitated from normal MEF and HEL 
fibroblast with Par-4 antibody, and Par-4 was reciprocally co-immunoprecipitated 
with UACA antibody (Figure 2.3 A). A comparison of p53+/+ and p53-/- MEFs 
indicated that UACA was lower in p53+/+ normal cells and mouse tissues relative 
to p53-/- cells and mouse tissues. Nutlin-3a suppressed the expression of UACA 
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in p53+/+ but not p53-/- MEFs (Figure 2.3B), implying suppression of UACA 
expression by p53. Our previous studies (Burikhanov et al., 2013) have shown 
that UACA is regulated by NF-κB and, as expected, UACA expression was 
inhibited by PS-1145 (Figure 2.3B).   
UACA levels in p53+/+ and p53-/- MEFs correlated inversely with the levels of Par-
4 secreted in the CM. Restoration of p53 activity in p53-/- MEFs by p53-
adenoviral infection or at 32oC in 10(1)/Val5 fibroblasts, which contain a 
temperature-sensitive mutant of p53 (Harvey and Levine, 1991; Wu and Levine, 
1994), suppressed the expression of UACA and induced secretion of Par-4 
(Figure 2.3C). Moreover, knock-down of UACA using several different mouse 
and human siRNA duplex pools, resulted in elevated Par-4 levels in the CM of 
p53+/+ MEFs and HEL cells (Figure 2.3D). By contrast, knock down of UACA in 
p53-/- MEFs did not elevate the secretion of Par-4 (Figure 2.3D), indicating that 
p53 function was necessary to regulate the secretion of Par-4. Consistently, 
ectopic expression of UACA inhibited the secretion of Par-4 (Figure 2.3E). UACA 
binding to Par-4 was essential to prevent Par-4 secretion, and accordingly, 
mutant UACA (631-1413aa), which does not bind to Par-4 (Burikhanov et al. 
2013), was unable to prevent Par-4 secretion (Figure 2.3F). 
 
UACA and p53 reciprocally regulate Par-4 secretion via the classical 
pathway.    
Previous studies have indicated that Par-4 is secreted via the classical ER-Golgi 
pathway (Burikhanov et al., 2009), as well as via the exosomal pathway (Wang et 
al., 2012). On the other hand, p53 has been shown to promote secretion of 
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proteins via the exosomal pathway (Yu et al., 2006; Yu et al., 2009). To 
determine whether p53 activation leads to Par-4 secretion via the classical 
pathway, we used brefeldin A (BFA), which blocks the ER-Golgi pathway. BFA 
inhibited the secretion of Par-4 by p53 restoration at 32oC in 10(1)/Val5 
fibroblasts (Figure 2.3G, left panel). As both Nutlin-3a and PS-1145 induced the 
secretion of Par-4 in a p53-dependent manner, we investigated whether Par-4 
secretion following Nutlin-3a plus PS-1145 treatment occurred via the classical 
pathway. Nutlin-3a plus PS-1145-inducible secretion of Par-4 from p53+/+ MEFs 
was about 60% inhibited by BFA (Figure 2.3G, middle panel). These findings 
imply that p53 regulates the secretion of Par-4 largely by the classical pathway. 
Moreover, Par-4 secretion following UACA knock down in p53+/+ MEFs was 
inhibited by BFA (Figure 2.3G, right panel). Collectively, these findings indicate 
that UACA inhibition by siRNA, Nutlin-3a plus PS-1145, or p53 activation induces 
Par-4 secretion via the classical pathway. 
 
UACA is a direct target of p53.   
A potential p53-binding site (el-Deiry et al., 1992) is present in the DNA 
corresponding to exon 1 within the coding region of UACA (Figure 2.4A). P53 
suppresses the expression of UACA RNA, as judged by qRT-PCR (Figure 2.4B). 
In order to determine direct binding of p53 to its consensus binding site in UACA, 
we performed chromatin immuno-precipitation (ChIP) studies in p53-deficient 
cells that were infected with a GFP-p53 adenoviral expression construct. Our 
results showed that ectopically expressed p53 construct was bound to the 
putative p53 consensus element present in exon 1 within the UACA gene (Figure 
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2.4C). We next corroborated this finding with endogenous p53. HEL cells treated 
with Nutlin-3a, but not with vehicle, showed chromatin immuno-precipitation of 
endogenous p53 bound to the p53-consensus motif in UACA (Figure 2.4D). 
Consistently, Nutlin-3a treatment, which activates endogenous p53, suppressed 
the expression of UACA in HEL cells (Figure 2.4E).   
To determine whether p53 regulated UACA expression via its binding 
motif in an NF-κB activity-independent manner, we performed our experiments in 
IKKβ-/- MEFs, which lack NF-κB activity (Burikhanov et al., 2013; Li et al., 1999). 
Nutlin-3a treatment of IKKβ-/- MEFs resulted in suppression of UACA expression 
(Figure 2.4E). Moreover, ectopic p53 suppressed the expression of UACA 
containing the p53-binding motif, but did not suppress the expression of mutant-
UACA, which contained mutations in the p53-binding sequence in IKKβ-/- MEFs 
at both protein (Figure 2.4F, upper right panel), and mRNA levels (Figure 2.4F, 
lower panel). Together, these findings suggest that p53 suppressed the 
expression of UACA via its binding motif in an NF-κB-independent manner. Thus, 
UACA is a relevant target of p53, and p53 may regulate Par-4 secretion by down-
regulation of UACA. 
DISCUSSION 
The tumor suppressor p53 is known to suppress tumor growth by intracellular 
activation of growth arrest and apoptotic cell death pathways. However, p53 is 
mutated in over 50% of cancers, and mutant forms of p53 may render cancer 
cells resistant to both chemotherapy and radiation therapy. Lung cancer, the 
leading cause of deaths in the US, is often associated with inactivating mutations 
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in p53. We determined whether wild type p53 function in normal cells could be 
effectively propelled to target lung cancer cells. The present study revealed that 
p53 activation in normal cells induces paracrine apoptosis of p53-deficient lung 
cancer and prostate cancer cells. This action of p53 is mediated by the tumor 
suppressor protein Par-4. The paracrine effect of p53 activation on Par-4 
secretion was bolstered by co-parallel inhibition of NF-κB activity in normal cells. 
We noted that UACA binds to Par-4 and prevents it from being secreted, and 
inhibition of UACA by p53 activation and/or inhibition of NF-κB activity, or several 
different siRNAs, results in elevated secretion of Par-4. Importantly, Par-4 
secreted by cells following co-parallel activation of p53 and inhibition of NF-κB 
activity caused apoptosis in p53-deficient lung cancer cells but not normal cells. 
The physiological relevance of the findings was confirmed by studies indicating 
that normal cells in mice can be triggered to secrete pro-apoptotic Par-4 activity 
in circulation in a p53-dependent manner. The elevated levels of Par-4 in serum 
induced ex vivo apoptosis in tumor cells but not normal cells. Because our 
previous studies indicated a good correlation between inhibition of lung tumors in 
immuno-competent mice and induction of ex vivo apoptosis by Par-4 in the 
serum of these mice [Zhao et al, 2011], the activation of p53 to trigger pro-
apoptotic Par-4 protein secretion and elevate its systemic levels may be an 
effective strategy to induce apoptosis of cancer cells that metastasize through 
the circulatory route. Collectively, our findings suggest that secreted Par-4 
mediates the paracrine apoptotic effects of p53, and that secretagogues of Par-4 
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may therefore empower normal cells to execute paracrine tumor growth 
inhibition. 
Our findings indicate that Par-4 secretion following p53 activation occurs via the 
classical BFA-sensitive pathway. Secretion of Par-4 via this pathway is 
dependent on down-modulation of UACA, a novel functional target of p53. 
Chromatin immunoprecipitation experiments confirmed that p53 directly binds to 
its consensus motif in UACA. Importantly, p53 suppressed the expression of 
UACA in an NF-κB-independent manner. As UACA is a principal binding partner 
that sequesters Par-4 in normal cells, UACA inhibition by p53 is necessary to 
release Par-4 for secretion via the classical pathway. However, normal cells 
lacking p53 are deficient in Par-4 secretion despite UACA down-regulation, 
implying that p53 function is critical for Par-4 secretion and is suggestive of an 
additional role for p53 in triggering Par4 secretion. Several integral components 
of the classical ER-Golgi-transport vesicle/membrane fusion pathway are 
currently being investigated as targets for p53-dependent Par-4 secretion. Given 
that previous studies have indicated that p53 regulates protein secretion via the 
exosomal pathway, we tested whether Par-4 secretion is also regulated via the 
exosomes. Our findings indicate that of the total Par-4 secreted by cells, <5% is 
secreted via the exosomal pathway and the large majority is secreted by the 
classical pathway (unpublished data).  
In summary, our findings suggest that the tumor suppressor p53 regulates the 
secretion of the pro-apoptotic, tumor suppressor Par-4 via the classical pathway 
by suppressing UACA, and that Par-4 executes the paracrine apoptotic effects of 
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p53. As systemic Par-4 inhibits the growth of lung tumors [Zhao et al, 2011], Par-
4 secretagogues can be exploited to activate p53 and unleash the power of 
normal cells in the tumor micro- and macro-environment to elevate systemic Par-
4 and suppress tumor cell survival. 
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Figure 2.1: P53 activation in normal cells produces paracrine apoptosis in 
p53-deficient cancer cells 
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Figure 2.1: P53 activation in normal cells produces paracrine apoptosis in 
p53-deficient cancer cells  
(A) Activation of p53 in MEFs induces apoptosis of co-cultured p53-
deficient cancer cells. Co-cultures of p53+/+ or p53-/- MEFs with the 
indicated cancer cells, were treated with vehicle (v), Nutlin-3a (N, 10 µM) 
and/or PS-1145 (P, 10 µM) for 24 h. The cells were subjected to ICC for 
cytokeratins to detect epithelial cancer cells and for active caspase-3 to 
determine apoptotic cells. Performed by Dr. Ravshan Burikhanov. 
 
(B) Apoptosis of cancer cells by CM obtained from p53-activated MEFs. 
P53+/+ or p53-/- MEFs were treated with vehicle (v), Nutlin-3a (N, 10 µM) 
and/or PS-1145 (P, 10 µM) for 24 h, and their CM was transferred to normal 
(HEL) or p53-deficient cancer (H1299) cells. Apoptotic cells were scored after 
24 h by ICC for active caspase-3 (left panel). Similarly, p53+/+ or P53-/- MEFs 
and HEL cells were treated with vehicle (v), Nutlin-3a (N, 10 μM) and/or PS-
1145 (P, 10 μM) for 24 h and the CM was transferred to various normal 
(HEL) and p53-deficient cancer (H1299, HOP-92) cell lines. After 24 h, the 
cells were scored for apoptosis (right panel). 
 
(C) Co-parallel activation of p53 and inhibition of NF-κB activity additively 
increases Par-4 secretion in fibroblasts. MEFs were treated with vehicle 
(v), Nutlin-3a (N) and/or PS-1145 (P) for 24 h, and their CM, as well as 
whole-cell lysates were subjected to Western blot analysis for Par-4. β-actin 
was used to normalize loading of lysate. Coomassie blue-stained albumin in 
the serum was used to normalize loading of CM. Par-4 secretion, but not 
Col1A1 secretion, was dependent on the p53 status of the cells. Fold change 
in secreted Par-4 is shown. 
 
(D) Par-4 secretion in response to p53 activation does not require 
apoptosis of the normal cells. P53+/+ or P53-/- MEFs were treated with z-
VAD-fmk (2 µM) and with Nutlin-3a (N, 10 μM) plus PS-1145 (P, 10 μM) or 
vehicle (v) for 24 h. The CM was examined for Par-4 levels by Western blot 
analysis. 
 
(E) Par-4 secretion is critical for the paracrine effect resulting from 
simultaneous p53-activation and NF-κB-inhibition. The CM from p53+/+ 
cells treated with Nutlin-3a + PS-1145 was incubated with polyclonal 
antibody for Par-4 or PTEN control, and then added to H1299 cells. 
Apoptosis of H1299 cells was scored after 24 h by ICC for active caspase 3 
(left panel). Par-4+/+ and Par-4-/- MEFs were treated with Nutlin-3a + PS-1145 
(N+P) or vehicle, then the CM was applied to the indicated cell lines, and 
apoptotic cells were scored by ICC for active caspase-3 (middle panel). 
Expression of Par-4 in CM was verified on Western blots (right panel). 
Performed by Dr. Ravshan Burikhanov. 
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(F) Doxorubicin induces paracrine apoptosis of cancer cells by Par-4 
secretion. PC-3 cells were treated with 100 nM doxorubicin (Dox) or vehicle 
for 24 h and scored for apoptosis by ICC for active caspase-3. Note 100 nM 
Dox does not directly induce apoptosis in PC-3 cells (middle panel). Par-4+/+ 
or Par-4-/- MEFs were treated with 100 nM doxorubicin (Dox) or vehicle for 24 
h and the CM from these cells was transferred to PC-3 cells; after 24 h the 
PC-3 cells were scored for apoptosis (left panel). Elevation of Par-4 in the 
CM of doxorubicin (Dox)- or vehicle (v)-treated Par-4+/+ or Par-4-/- MEFs was 
confirmed by Western blot analysis (right panel). Right panel performed by 
Dr. Ravshan Burikhanov. 
 
(A, B) Asterisk (*) indicates statistical significance (P < 0.001) by the Student t 
test. (**) indicates that N+P is significantly (P < 0.001) more effective than 
individual treatments among different cell lines based on two-way ANOVA 
followed by Bonferroni correction. 
(E, F) (**) indicates that the indicated treatments are significantly (P < 0.001) 
more effective than their respective control groups based on two-way 
ANOVA followed by Bonferroni correction. 
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Figure 2.2: Activation of p53 in mice induces systemic expression of Par-4 
pro-apoptotic activity 
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Figure 2.2: Activation of p53 in mice induces systemic expression of Par-4 
pro-apoptotic activity. 
 
(A) P53 function is essential for induction of systemic Par-4 in mice. Serum 
samples from p53+/+ mice (4 µl per lane) and p53-/- mice (8 µl per lane) (left 
panel); and also from p53+/+, p53-/-, and Par-4-/- mice (right panel) injected via 
i.p. route with either vehicle (v) or with Nutlin-3a + PS-1145 (N+P) were 
examined for Par-4 expression by Western blot analysis using serum 
albumin to normalize loading. Data are representative of 4 mice per 
treatment. Performed by Dr. Ravshan Burikhanov. 
 
(B) Serum from Nutlin-3a plus PS-1145-treated p53+/+ mice induces ex vivo 
apoptosis of cancer cells. Serum samples collected from p53+/+, p53-/-, and      
Par-4-/- mice injected i.p. with either vehicle (lower panel) or with Nutlin-3a + 
PS-1145 (N+P) (upper panel) was applied at a final concentration of 10% to 
the indicated normal or cancer cell lines. The cells were scored for apoptosis 
after 24 h. Fetal bovine serum (FBS, 10%) was used as an additional control. 
Performed by Dr. Ravshan Burikhanov. 
 
(C) Secreted Par-4 is essential for the paracrine effect of p53 activation. 
Serum samples collected from p53+/+ mice treated with vehicle or Nutlin-3a + 
PS-1145 (N+P) were pre-incubated with Par-4 antibody, control PTEN 
antibody or no antibody (Ab), and then applied on lung cancer cells. After 24 
hours of treatment, the cells were scored for apoptosis. Performed by Dr. 
Ravshan Burikhanov. 
 
(B) Asterisk (**) indicates there is a significant (P < 0.001) increase in apoptosis 
of cancer cells with serum obtained from p53+/+ mice treated with N+P, 
based on two-way ANOVA followed by Tukey’s test.  
(C) Asterisk (*) indicates statistically significant (P< 0.001) increase in apoptosis 
of cancer cells with serum obtained from wild-type mice treated with N+P, 
and (**) indicates significant (P< 0.001) reduction in this effect when Par-4 
antibody is used. The statistical analysis was performed using two-way 
ANOVA followed by Tukey’s test. 
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Figure 2.3: P53 stimulates Par-4 secretion by suppressing the expression 
of UACA 
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Figure 2.3: P53 stimulates Par-4 secretion by suppressing the expression 
of UACA.  
 
(A) UACA binds to Par-4 in fibroblasts. Whole-cell lysates of human lung 
fibroblasts HEL and p53+/+ MEFs were subjected to co-immunoprecipitation 
with Par-4, UACA, or p65/NF-κB (control) antibody. The immunoprecipitates 
and input lysates were examined by Western blot analysis to anallyze 
binding interaction between Par-4 and UACA in fibroblasts. 
 
(B) P53 down-regulates UACA. Whole-cell lysates from p53+/+ and p53-/- MEFs 
that were either untreated or treated with vehicle (v), Nutlin-3a (N, 10µM), or 
PS-1145 (P, 10 µM) for 24 hours (left 3 panels) ; or whole-tissue lysates of 
highly vascular organs obtained from p53+/+ and p53-/- mice (right 3 panels), 
were examined for UACA by Western blot analysis. Right panel performed 
by Dr. Ravshan Burikhanov.  
 
(C) Restoration of p53 activity inhibits UACA expression and promotes 
Par-4 secretion.  CM or whole-cell lysates from p53+/+ and p53-/- MEFs were 
subjected to Western blot analysis for UACA or Par-4 expression. Results 
indicate an inverse relation between UACA expression and Par-4 secretion 
(left panel). P53-/- MEFs were infected with GFP-tagged p53- or GFP-
producing adenoviral constructs (middle panel).  Also, the mouse fibroblasts 
10(1), which do not express any p53, and 10(1) derived Val5 cells, which are 
engineered to stably over-express wild-type p53 at 32 °C or mutant p53 at 
37 °C, were grown at 37oC or shifted to 32oC to activate p53 (right panel). 
Expression of the indicated proteins in the CM or whole-cell lysate was 
examined by Western blot analysis. Middle panel performed by Dr. Ravshan 
Burikhanov. 
 
(D) UACA inhibits Par-4 secretion. UACA expression was knocked down in 
mouse (p53+/+ MEF) and human (HEL) cells with distinct siRNA pools from 
two different sources- Dharmacon (D), and SantaCruz Biotechnology, Inc. 
(SC), and the CM, as well as the whole cell lysates, were subjected to 
Western blot analysis. C, control (scrambled) siRNA. Performed by Dr. 
Ravshan Burikhanov. 
 
(E) Ectopic expression of UACA inhibits the secretion of Par-4. MEFs from 
Par-4-/- mice were co-transfected with Par-4 expression construct plus vector 
control, Par-4 and UACA expression construct (1:1 ratio), or with vector 
control. Transfected populations were selected, confirmed for stable 
expression of Par-4 and UACA using whole-cell lysates, and then secretion 
of Par-4 in the CM was examined by Western blot analysis. Performed by Dr. 
Ravshan Burikhanov. 
 
(F) UACA binding to Par-4 is essential in order to prevent Par-4 secretion. 
Par-4+/+ MEFs were transfected with expression constructs for Red 
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Fluorescent Protein (RFP; vector), RFP-tagged UACA, or RFP-tagged UACA 
deletion mutants, 1-630 (which binds to Par-4) or 631-1413 (which does not 
bind to Par-4) (Burikhanov et al., 2013). Transfected populations were 
selected, confirmed for stable expression of UACA or UACA-mutants using 
whole-cell lysates, and secretion of Par-4 in their CM was determined by 
Western blot analysis. Diagrammatical representations of full-length UACA 
and its deletion mutants are shown (right panel). Performed by Dr. Ravshan 
Burikhanov. 
 
(G) P53 activation and UACA inhibition promotes secretion by a BFA-
sensitive pathway. 10(1)/Val5 fibroblasts grown at 32oC were treated with 
BFA (1 µg/ml) or vehicle (v) for 3 h (left panel). UACA expression was 
knocked down in MEFs (p53+/+) with Nutlin-3a plus PS-1145 (N+P; 10 µM 
each) or vehicle (v) control (middle panel), or with an siRNA pool (from 
Dharmacon) (right panel), and then the cells were further placed in the 
presence of BFA or vehicle (v) for 3 h. The CM, as well as the whole-cell 
lysates, were subjected to Western blot analysis. Right panel performed by 
Dr. Ravshan Burikhanov. 
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Figure 2.4: P53 directly binds to UACA and inhibits its expression 
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Figure 2.4: P53 directly binds to UACA and inhibits its expression. 
(A) Comparison of the p53 response elements in UACA and p21, and 
location of wild type p53 binding motif and mutations introduced 
in UACA.  The p53 binding site consensus DNA motif is shown along 
with the p53-binding motifs in UACA and p21. The indicated mutations 
were introduced at C4, G7, C14 and G17 into the p53-binding motif of 
UACA. P21 has two p53-binding motifs (#1 and #2). The base pairs in 
the p53-binding motif of p21 that deviate from the p53 consensus 
binding motif are underlined. Mutant-UACA with the altered p53-
binding site was generated by PCR using mutant-UACA primers and 
wild type UACA DNA as template. Fidelity of the constructs was 
confirmed by Retrogen Inc., CA. 
 
(B) P53 inhibits the expression of UACA RNA. Cells were infected with 
either control GFP-producing adenovirus or GFP-tagged p53-
producing adenovirus for 24 h. Total RNA was isolated from each of 
the samples and subjected to qRT-PCR (upper panel) or subjected to 
Western blot analysis (lower panel). Performed by Dr. Shirley Qiu. 
 
(C) P53 binds to its consensus binding motif in UACA. A putative p53 
binding motif (5’-GGAC4GTG7CCCGGCC14CCG17CGTC-3’; where C4 
and G7 have been previously shown to be critical) is present in the 
coding region of UACA. P53-deficient cells were infected with GFP-
tagged p53- or GFP-producing adenovirus and subjected to ChIP 
analysis with p53 antibody (Ab) or control rabbit Ab, and 
immunoprecipitated DNA fragments were analyzed by PCR with 
primers flanking the p53 binding site. 
 
(D) Endogenous p53 binds to its consensus binding motif in UACA. 
HEL cells were treated with Nutlin-3a (N) or vehicle (v) for 24 h and 
subjected to ChIP analysis with p53 antibody (Ab) or control rabbit IgG 
Ab, and immunoprecipitated DNA fragments were analyzed by PCR 
with primers flanking the p53-binding site in UACA. Primers flanking 
the p53-binding motif #1 in p21 (Figure 2.4A) or for GAPDH (which 
does not contain a p53-binding site), were used as positive or negative 
control, respectively. Input samples for each set of primers are shown. 
 
(E) Nutlin-3a causes inhibition of endogenous UACA expression in 
an NF-κB independent manner. IKKβ-/- MEFs or IKKβ+/+ MEFs and 
HEL cells, as controls, were treated with Nutlin-3a or vehicle for 24 h, 
and whole-cell lysates were subjected to Western blot analysis for 
UACA, p53 or actin. 
 
(F) P53 regulates UACA expression via its binding motif in an NF-κB 
activity-independent manner. IKKβ-/- MEFs or IKKβ+/+ MEFs, as 
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controls, were co-transfected with the indicated expression constructs. 
Whole-cell lysates were subjected to Western blot analysis for UACA, 
p53 or actin (top panels) or RNA was prepared from the cells and 
subjected to reverse transcriptase PCR for UACA and 18S rRNA 
(bottom panel).  Wild type (wt) UACA contained wild type p53-binding 
motif 5’-GGAC4GTG7CCCGGCC14C CG17CGTC-3’, and mutant (m) 
UACA contained mutations 5’-GGAT4GTA7 CCCGGCG14CCA17CGTC-
3’ in the p53 binding motifs.  
Top right panel performed by Dr. Ravshan Burikhanov, and bottom 
panel performed by Nikhil Hebbar. 
 
(B) Asterisk (*) indicates statistical significance (P< 0.001) by the Student t test. 
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Fig 2.5: Generation of PAWR knock-out mice 
 
 
 
 
 
Fig 2.5: Generation of PAWR knock-out mice: Diagrammatical illustration of 
the targeting cassette used in the generation of PAWR knock-out mice, as 
described in Materials and Methods section. 
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CHAPTER 3: PAR-4 REGULATES P53 STABILITY 
INTRODUCTION 
Since the discovery of Par-4 in 1994, research in this field has primarily revolved 
around the apoptotic function of Par-4. The apoptotic nature of Par-4 is 
exemplified by its elevated expression in cells undergoing active apoptosis, for 
example, granulosa cells of atretic ovarian follicles, interdigitating web cells of the 
mouse embryo, involuting tadpole tails, and dying neurons during neuronal 
development (El-Guendy and Rangnekar, 2003). Par-4 is reported to be an 
essential downstream regulator of the apoptotic action of various physical and 
chemical agents, such as TRAIL, Vincristine, Adriamycin, and Ionizing Radiation 
(IR) (Gurumurthy et al., 2005; Ranganathan and Rangnekar, 2005). In addition, 
several studies in cell culture models have emphasized the role of Par-4 in 
sensitizing different cell types to a wide array of apoptotic stimuli, namely, growth 
factor withdrawal; tumor necrosis factor-α (TNF- α); ultraviolet (UV), X-ray and 
gamma radiation (Chakraborty et al., 2001; Chendil et al., 2002; El-Guendy and 
Rangnekar, 2003; Nalca et al., 1999); as well as to chemotherapeutic agents 
such as Docetaxel (Pereira et al., 2013) and 5-Fluorouracil (5-FU) (Wang et al., 
2010). Induction of cancer cell-specific apoptosis by Par-4 in involves 
concomitant activation of the pro-death pathway mediated by Fas/Fas ligand 
(Fas/FasL) and inhibition of pro-survival pathway mediated by Nuclear Factor- 
kappa B (NF-κB) (Chakraborty et al., 2001). In addition, some reports have cited 
Par-4-mediated repression of the Bcl-2 gene as a factor contributing to 
apoptosis-sensitizing action of Par-4 (Chendil et al., 2002; Wang et al., 2010).  
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A predominant observation across a broad spectrum of human cancer cells 
denotes that cells that have down-modulated or lost the expression of Par-4 
exhibit increased resistance to apoptosis due to therapeutic agents such as 
Etoposide, Vincristine, Adriamycin, and Cisplatin (Affar el et al., 2006; Alvarez et 
al., 2013; Tan et al., 2014). Low Par-4 expression was also identified as the 
reason for diminished sensitivity of oncogene-driven breast cancer cells to 
apoptosis following oncogene inhibition (Alvarez et al., 2013). Furthermore, 
inactivation of Par-4 by Akt-mediated phosphorylation and subsequent 
cytoplasmic retention was also noted to inhibit apoptosis in prostate cancer 
(Goswami et al., 2005). Consistent with these observations, reduced Par-4 
expression is known to correlate with decreased overall survival in pancreatic 
(Ahmed et al., 2008) and breast cancers (Mendez-Lopez et al., 2010; Nagai et 
al., 2010), and glioblastomas (Liu et al., 2014b), as well as reduced recurrence-
free survival in breast cancers (Alvarez et al., 2013).  
Despite such glaring instances which place Par-4 right at the center of apoptosis 
evasion, therapy resistance, and poor disease prognosis, not enough is 
understood about the mechanism(s) that contribute to the apoptotic pathway 
mediated by Par-4 in response to various physical and chemical stimuli. High 
resistance to apoptosis shown by Par-4-null cancer cells is reminiscent of 
therapeutic resistance conferred by p53 loss (or mutation/inactivation) to UV 
(Barley et al., 1998; Mirzayans et al., 2013), IR (Lowe et al., 1993b; Mirzayans et 
al., 2013), and to chemotherapeutic agents such as Adriamycin, 5-FU (Lowe et 
al., 1993a), as well as to Etoposide and Vincristine (Dudley et al., 2008). All of 
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such studies have been performed in cancer cells, which by dint of genomic 
instability, might harbor many more genetic changes than just Par-4 loss or 
down-regulation. One study (Affar el et al., 2006) has utilized primary cells, but 
the MEFs used do not represent true Par-4 loss because they express a leucine 
zipper deletion mutant of Par-4, which still contains the potent SAC domain. In 
this study, for the first time, we study the functional relevance of Par-4 loss using 
MEFs prepared from Par-4 knock-out embryos. We demonstrate that loss of Par-
4 results in a significant reduction in p53 expression, as well as function. In 
addition, our findings indicate that attenuation of p53 stabilization renders the 
Par-4-null cells resistant to apoptosis in response to genotoxic stresses such as 
treatment with 5-FU or IR. Mechanistically, Par-4 appears to stabilize p53 by 
preventing Akt-mediated phosphorylation of Mdm2, thereby inhibiting stabilization 
and nuclear translocation of Mdm2.  
MATERIALS AND METHODS 
Cell lines and generation of Par-4+/+ and Par-4-/- MEFs 
A549 and HOP92 lung cancer cells were from ATCC; and were cultured in 
RPMI+10% FBS. Cells expressing constitutively active Akt were kindly provided 
by Dr. Morris Birnbaum (University of Pennsylvania). 
Par-4-/- and Par-4+/+ MEFs were generated from C57BL/6 Par-4 knock-out mice 
and from their wild-type littermates (Burikhanov et al., 2014a), and were grown in 
DMEM supplemented with 10% Fetal Bovine Serum (FBS). Briefly, 14.5 days old 
embryos were isolated from female uteri; heads were severed and used for 
genotyping. The embryos were cleaned to remove unwanted tissues; each 
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embryo was placed in a separate petri dish, and aseptically minced into fine 
fragments with a clean razor blade. The resulting pulp was transferred into a tube 
containing trypsin, pipetted to disintegrate tissue clumps, and incubated for 
approximately 10 minutes. This process was repeated until a satisfactory cell 
suspension was obtained. The cell suspension was then transferred to a tube 
containing pre-warmed media, centrifuged, and plated in DMEM supplemented 
with 15% FBS, non-essential amino acids (NEAA), glutamine, and sodium 
pyruvate.  
Generation of stable cell lines   
pLKO.1 lentiviral vectors expressing control short hairpin (sh)RNA or shRNAs 
targeting Par-4 were gift from Dr. Zhang. pLKO.1 lentiviruses were packaged by 
co-transfecting the pMD2.G (VSVG) envelope plasmid and Gag, Pol expressing 
psPAX2 packaging plasmid (both from Addgene) into HEK-293T cells. Cells were 
cultured for 48 hours after transfection and the lentiviral particles collected from 
the supernatants were used to transduce A549 and HOP92 cell with or without 
concentration using Lenti-X Concentrator (Clontech). Cells were subsequently 
selected with puromycin and gene silencing efficiency was analyzed by 
immunoblotting for the respective proteins. 
Plasmid constructs and reagents 
Luciferase construct containing wild-type p53 consensus binding sites (PG13) 
was purchased from Addgene. Par-4 shRNA construct in pLKO.1 vector, and 
Adenoviral p53 constructs were kindly provided by Dr. Zhang and Dr. Wafik el-
Deiry (Penn State University), respectively. Par-4 adenoviral constructs have 
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been described previously (Chakraborty et al., 2001). Nutlin-3a was purchased 
from Cayman Chemicals. Cycloheximide and 5-FU were from Sigma. 
Western blotting and antibodies 
Cell lysates or tissue extracts were subjected to gel electrophoresis by SDS-
PAGE followed by western blotting with appropriate antibodies. Par-4 (R-332), 
Akt-1 (B-1), Egr-1 and p53 (DO-1) were from Santa Cruz Biotechnology. Mouse 
specific p53 antibody (mAb, 1C12), cleaved caspase-3 (D175), phospho-Akt (S-
473), and phospho-Mdm2 (S166) antibodies were from Cell Signaling 
Technology. Mdm2 antibody (Ab3) was purchased from Calbiochem, and β-actin 
antibody from Sigma. 
Reverse transcriptase-Polymerase Chain Reaction (RT-PCR) analysis 
Total RNA was extracted from lung tissues harvested from Par-4+/+ and Par-4-/- 
mice and preserved in RNAlater solution (Qiagen) RNeasy Plus Mini kit (Qiagen). 
Reverse transcription was performed to synthesize cDNA with random hexamers 
using SuperScript III First-Strand Synthesis System (Invitrogen), followed by 
PCR. PCR products were then subjected to agarose gel electrophoresis. The 
primers used for p53 and 18S are listed below. 
Mouse p53 RNA  
Forward primer: 5’- tat gtg cac gta ctc tcc tc -3’  
Reverse primer: 5’- tgc tgt gac ttc ttg tag atg -3’  
18S RNA  
Forward primer: 5’- gta acc cgt tga acc cca tt -3’  
Reverse primer: 5’- cca tcc aat cgg tag tag cg -3’  
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Luciferase assay 
Cells were co-transfected with the PG-13 wild-type p53-luc or empty pGL3-luc 
reporter plasmid together with β-galactosidase for normalization. 24 hours after 
transfection, cells were washed, lysed, and the cell extracts were mixed with 
luciferase substrate Steadylite plus from PerkinElmer. Luminescence was 
assayed using TopCount plate reader.  
Apoptosis assays 
Apoptotic nuclei were identified by immunocytochemical (ICC) analysis for active 
caspase-3, and/or by 4, 6-diamidino-2-phenylindole (DAPI) staining. A total of 
three independent experiments were performed; and approximately 500 cells 
were scored in each experiment for apoptosis under a fluorescent microscope. 
Statistical Analysis 
All experiments were performed in triplicate to verify reproducibility. Two-way 
ANOVA (with appropriate post-hoc test) and Student’s t-test were used to 
calculate p-values. 
RESULTS 
Par-4 is necessary for apoptosis induction by 5-FU and IR 
In order to assess the cellular role of Par-4 in apoptosis, we used genetically 
matched Par-4+/+ or Par-4-/- mouse embryonic fibroblasts (MEFs) and 
investigated their response to genotoxic stresses exerted by treatment with 5-
Fluorouracil (5-FU) or Ionizing Radiation (IR). We noted that, after 24 hours of 
treatment, Par-4+/+ MEFs underwent a gradual dose-dependent increase in 
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apoptosis with 5-FU and IR treatment, whereas Par-4-/- MEFs remained 
significantly resistant to these agents (Fig. 3.1A and 3.1B).  
Par-4 is required for stress-induced p53 stabilization, transcriptional 
activity, and apoptosis 
It is widely known that wild-type p53 undergoes rapid activation and stabilization 
in response to treatment with 5-FU and IR, and induces p53-dependent 
apoptosis in the event of intractable cellular damage (Bunz et al., 1999; Lowe et 
al., 1993a; Mirzayans et al., 2013). Since both Par-4+/+ and Par-4-/- MEFs 
possess wild-type p53, treatment with 5-FU and IR was therefore expected to 
elicit a normal p53 stabilization response in both the MEFs. Hence, we decided 
to probe for p53 accumulation in response to these treatments in the wild-type 
and Par-4-null MEFs. Par-4+/+ MEFs, as expected, exhibited p53 accumulation 
when treated with 5-FU (10μM) or IR in a time- and dose-dependent manner. 
However, we were most intrigued to notice little or no induction of p53 protein 
expression in Par-4-/- MEFs after such treatments (Fig. 3.2A and 3.2B). In order 
to determine that Par-4-null cells were not inherently defective in regulating the 
expression of stress-inducible genes, we tested for the expression of Early 
growth response-1 gene product (Egr-1) in 5-FU treated samples. Our results 
showed a steady increase in Egr-1 protein expression 30 minutes after 5-FU 
treatment in both Par-4+/+ and Par-4-/- MEFs. In addition, we observed similar 
temporal sequence of Egr-1 induction and degradation in both Par-4+/+ and Par-4-
/- cells. Interestingly, p53, which is known to be transcriptionally regulated by Egr-
1, was not appreciably induced in Par-4-/- cells in spite of robust Egr-1 induction 
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(Fig. 3.2A). Next, we assessed p53 function in both the MEFs using PG13-luc, a 
luciferase reporter construct containing 13 copies of the wild-type p53-binding 
consensus sequence. When we co-transfected the PG13-luc construct along with 
β-galactosidase (for normalization), our results indicated that lower expression of 
p53 protein in Par-4-/- cells also translated to a corresponding reduction in p53 
transcriptional activity (Fig 3.2C). 
These results implied that Par-4-/- MEFs were resistant to 5-FU- or IR-induced 
apoptosis because of impaired p53 activation/stabilization and function. We 
sought to investigate if the apoptosis resistance exhibited by Par-4-/- MEFs could 
entirely be ascribed to attenuated p53 expression. For this purpose, Par-4-/- 
MEFs were infected with either GFP (control), or GFP-p53, or GFP-Par-4 
adenovirus constructs, and after confirming the expression of these constructs, 
these cells were treated with either vehicle control, or with different doses of 5-
FU for 24 hours, after which they were analyzed for apoptosis. As seen in Fig. 
3.2D, re-introducing Par-4 into Par-4-null system restored the apoptotic potential 
of 5-FU in these cells. Replenishing p53 levels in these cells showed an increase 
in apoptosis; however, this effect did not match the extent of apoptosis produced 
by Par-4 over-expression, and thus represented only a partial recovery of 5-FU-
induced apoptosis. Therefore, Par-4-induced apoptosis in response to 5-FU 
appears to be only partially mediated by p53, and also involves p53-independent 
pathways. 
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Par-4 is required for p53 protein stability under basal conditions 
Based on our observation that p53 stabilization in response to genotoxic stresses 
was so severely compromised in the absence of Par-4, we decided to assess if 
there was any difference in basal expression of p53 in various tissues harvested 
from Par-4+/+ and Par-4-/- animals, as well as in MEFs derived from these 
animals. As is evident in Fig. 3.3A, Par-4-/- tissues and MEFs showed markedly 
reduced expression of p53 in comparison to their Par-4+/+ counterparts; the 
difference being more pronounced in tissues than in MEFs. Next, we sought to 
verify that our results reflected a direct role of Par-4 in p53 stability. We re-
introduced Par-4 into Par-4-null MEFs by adenoviral infection, and assessed p53 
expression 24 hours post infection. Interestingly, with increasing dosage of Par-4 
re-expression in Par-4-/- cells, p53 expression also showed gradual stabilization 
(Fig. 3.3B).  
Moreover, we wanted to ascertain that our observation was not limited to Par-4 
knock-out animals and MEFs produced from them, but was a global effect of Par-
4 loss. To test this, Par-4 expression was knocked-down in A549 and HOP92 
lung cancer cells by transfection of lentiviral shRNA particles, and the cells stably 
expressing the shRNA were selected with the help of Puromycin. Knock-down of 
Par-4 expression in A549 cells, which possess wild-type p53, resulted in lowering 
of p53 expression, similar to our results in Par-4-/-  background; whereas in 
HOP92 cells, which possess mutant p53, Par-4 knock-down had no effect (Fig. 
3.3C). We could draw two major inferences from this result: a) Par-4 does not 
regulate the p53 promoter, because if it did, Par-4 knock-down should have 
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resulted in reduced expression of mutant p53 in HOP92 cells also. b) Par-4 is 
required for p53 protein stability. As a confirmatory step, we performed reverse 
transcription-polymerase chain reaction (RT-PCR) on RNA derived from lungs of 
Par-4+/+ and Par-4-/- mice, and as depicted in Fig. 3.3D, p53 mRNA in these 
samples did not exhibit any difference in expression. These experiments clearly 
implicated a role for Par-4 in p53 stabilization, and hence we decided to 
investigate p53 protein stability in cells with or without Par-4. 
Par-4 loss results in elevated Mdm2 activity and reduced p53 stability 
We examined p53 protein expression in isogenic pairs of cell lines differing only 
in their expression of Par-4 (with Par-4 levels either intact, or entirely absent or 
knocked down) after treatment with Cycloheximide (CHX) (10μg/ml). CHX inhibits 
de novo protein synthesis, and hence would help us study the kinetics of p53 
degradation, and therefore, its overall stability, in the presence or absence of 
Par-4. In Par-4-null MEFs, and in A549 cells in which Par-4 is knocked-down 
(A549 Par-4 sh), stability of p53 protein appeared to be significantly reduced in 
comparison to Par-4+/+ MEFs (Fig. 3.4A) and to A549 cells with normal levels of 
Par-4 (A549 Con sh) (Fig. 3.4B), respectively. Moreover, as expected, the same 
treatment of HOP92 cells revealed highly stable form of mutant p53, high 
expression of which was maintained irrespective of CHX treatments or Par-4 
status (Fig. 3.4C). 
On the basis of these results, we hypothesized that p53 faced an accelerated 
rate of degradation, and therefore displayed less stability in the absence of Par-4, 
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which led us to evaluate Mdm2-mediated p53 degradation in the presence and 
absence of Par-4. Mdm2, an E3 ubiquitin ligase, is the best characterized 
negative regulator of p53 stability. We sought to investigate if changes in the 
expression and/or activity of Mdm2 could account for decreased stability of p53 
in Par-4-null situation. To this end, we used Nutlin-3a to inhibit Mdm2-p53 
interaction (Vassilev et al., 2004) in both Par-4+/+ and Par-4-/- MEFs, the rationale 
being p53 expression should rise to comparable levels in both the MEFs if Mdm2 
was involved. We treated these MEFs for 24 hours with Nutlin-3a, and further 
incubated them in the presence of 10μg/ml CHX, or vehicle control, after which 
cell lysates were harvested at different time points and analyzed by western blot. 
As seen in Fig. (3.4D), treatment with Nutlin-3a significantly stabilized p53 
expression in both Par-4+/+ and Par-4-/- MEFs, and the discrepancy in p53 levels 
that was observed without Mdm2 inhibition was lost. This result clearly pointed 
towards elevated Mdm2-mediated degradation of p53 due to Par-4 loss. 
Several groups have reported that the cell survival kinase Akt negatively 
regulates p53 expression and function by phosphorylating Mdm2 at Serine-166 
(S166) and Serine-186 (S186) - an event that not only enhances Mdm2 ubiquitin 
ligase activity, but also promotes its translocation into the nucleus, where it 
induces rapid ubiquitination, subsequent nuclear export and proteasomal 
degradation of p53, thus effectively inhibiting p53 function (Gottlieb et al., 2002; 
Mayo and Donner, 2001; Ogawara et al., 2002; Schmitz et al., 2006; Zhou et al., 
2001). Previous research has revealed that loss of Par-4 results in elevation of 
Akt activity (Joshi et al., 2008). Therefore, we next performed serum stimulation 
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experiment with Par-4+/+ and Par-4-/- in order to evaluate the levels and activity of 
Akt as well as Mdm2 in these cells. When Par-4+/+ and Par-4-/- MEFs were made 
quiescent with serum-free media for four hours, and then stimulated by addition 
of serum, we found that Akt was activated to a greater degree in Par-4-/- cells 
than in Par-4+/+ [reflected by increased Akt phosphorylation at Serine 473 
(S473)]. Even more remarkable was the increase in levels of phospho-Mdm2 
(S166) in Par-4-/- cells (Fig. 3.4E). Re-stimulation with serum elicits a cell survival 
program wherein activated Akt rapidly phosphorylates Mdm2 at Serine-166 and 
at Serine-186; these phosphorylation events augment Mdm2-mediated 
ubiquitination and degradation of p53. Our results suggest that the absence of 
Par-4 and consequent elevation of Akt activity promotes the activation of Akt-
Mdm2-p53 axis, which leads to reduced expression and attenuated function of 
p53. These results were further validated using cells expressing constitutively 
active form of Akt. When compared to wild-type cells, cells with constitutively 
active Akt displayed, as expected, increased Akt phosphorylation at S473; very 
low levels of Par-4; enhanced Mdm2 (S166) phosphorylation; and significantly 
diminished expression of p53 (Figure 3.4F), which corroborates our findings with 
Par-4-null MEFs. 
DISCUSSION 
 
In this study, we have identified a novel role for the tumor suppressor Par-4 in 
regulating the expression and function of another tumor suppressor- p53. P53, a 
stress-induced transcription factor, constitutes a hub of signaling networks 
controlling critical cellular and organismal phenotypes. Many therapeutic agents 
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and genotoxic stresses exert their apoptotic effect by activating and stabilizing 
p53, which then sets into motion complex cellular machineries to orchestrate 
apoptotic cell death. Consequently, p53 loss or mutation, which occurs in more 
than half of human cancers, is known to confer resistance to apoptosis by 
various radio- and chemo-therapeutic agents, namely, UV, IR, 5-FU, Adriamycin, 
Etoposide, Vincristine etc (Lowe et al., 1993a).  Interestingly, Par-4 loss or down-
regulation is also deemed to confer chemo- or radio-resistance, as documented 
by a number of research studies conducted on cell culture systems, mouse 
models, as well as tumor specimens. This study, performed on MEFs obtained 
from either wild-type or Par-4 knock-out mice, also demonstrates that lack of Par-
4 results in increased resistance to apoptosis by 5-FU and IR (both of which are 
known to activate p53) in spite of the presence of wild-type p53 in both cell types. 
Alvarez et al., 2013, have also observed that breast cancer cells in which Par-4 
expression is down-regulated are resistant to apoptosis by p53-activating agents 
such as Adriamycin despite possessing wild-type p53. It is thus interesting to 
note how the presence of wild-type p53 appears to be ineffectual in causing 
apoptosis when Par-4 expression is lost or down-regulated. Our study hereby 
presents evidence that p53 expression and function is severely compromised by 
loss of Par-4; and therefore serves to shed light on the potential mechanism of 
therapy resistance engendered by Par-4 loss or down-regulation. 
Our results show that p53 expression is reduced in Par-4-/- mice; in MEFs 
produced from Par-4-/- mice; as well as in A549 cells in which Par-4 expression 
level has been knocked-down, as compared to their Par-4+/+ counterparts, which 
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indicates a definite role for Par-4 in regulating p53 expression. Furthermore, 
restoration of p53 expression in Par-4-/- cells with Par-4 re-introduction 
unequivocally corroborates this finding. The tight regulation of p53 protein level 
within cells is achieved not so much by changes in p53 transcription, but primarily 
by modulating Mdm2-mediated p53 degradation (Kruse and Gu, 2009; Oren, 
1999). Indeed, several lines of evidence in our study indicate that regulation of 
p53 by Par-4 is at the level protein stabilization, as outlined below.  
 Our RT-PCR data failed to reveal significant differences in p53 mRNA 
expression.  
 Par-4 knock-down failed to impact p53 levels in HOP92 lung cancer cell 
line, which carries an arginine to leucine mutation at position 175 (175 
R/L), and is known to possess relatively elevated basal levels of the 
mutant protein (O'Connor et al., 1997). Conversely, wild-type p53 levels in 
A549 lung cancer cells were effectively reduced by knock-down of Par- 4 
expression. This result rules out the possibility of Par-4 regulating p53 
promoter, because, if this effect were promoter-driven, expression levels 
of both the mutant and wild-type forms of p53 should have been impacted. 
 In addition, our cycloheximide experiments clearly indicate that, when de 
novo protein translation is inhibited, Par-4 loss or down-regulation results 
in a significant drop in wild-type p53 protein stability, thereby suggesting 
the presence of a hyper-active p53 degradation mechanism in cells that 
lack Par-4. 
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Mdm2, an E3 ubiquitin ligase with a high specificity for p53, is the best 
characterized negative regulator of p53 expression and function. Mdm2 
directly binds to p53, and tightly controls its basal levels via continuous 
ubiquitination and consequent degradation by the 26S proteasome (Haupt et 
al., 1997; Honda et al., 1997; Kubbutat et al., 1997). Mdm2-mediated 
ubiquitination also promotes nuclear export of p53; and this exit from the 
nucleus and cytoplasmic relocation is essential for its proteasomal 
degradation (Boyd et al., 2000; Geyer et al., 2000). In addition, Mdm2 
complexed with p53 is known to localize to regulatory regions of a number of 
p53 target genes and repress their transcriptional activation (Manfredi, 2010; 
Momand et al., 1992).  Upon exposure to genotoxic or other cellular stresses, 
interaction between Mdm2 and p53 is disrupted, which alleviates p53 from 
Mdm2-mediated repression, leading to p53 stabilization and transactivation of 
specific p53 target genes (Manfredi, 2010). The small molecule Mdm2 
antagonist Nutlin-3a, which binds to the p53-binding pocket in Mdm2 and thus 
disrupts Mdm2-p53 interaction, is shown to be sufficient to cause p53 
accumulation and transcriptional activation of p53 target genes (Vassilev et 
al., 2004). Our experiment with Par-4-/- cells treated with Nutlin-3a and CHX, 
and the stabilization of p53 observed thereof, distinctly implicates Mdm2-
mediated p53 degradation as a plausible cause for p53 protein instability in 
Par-4-null cells.  
Excessive Mdm2-mediated degradation of p53 could reflect either augmented 
expression, or elevated activity of Mdm2 protein, or both. Myriad of post-
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translational modifications on both p53 and Mdm2 have been described to 
influence the interaction between the two. Phosphorylation of Mdm2 by 
Akt/PKB serine/threonine kinase at two consensus sites- S166 and S186- is 
known to: a) enhance its E3 ubiquitin ligase activity; b) facilitate its 
translocation from the cytoplasm to the nucleus; c) lead to nuclear export of 
p53 and subsequent proteasomal degradation; and d) afford protection 
against p53-mediated apoptosis induced by genotoxic agents across a 
number of cellular and tumor paradigms (Gottlieb et al., 2002; Limesand et 
al., 2006; Mayo and Donner, 2001; Ogawara et al., 2002; Zhou et al., 2001). 
In this light, it is interesting to note that Par-4 has been shown to inhibit Akt 
activity (Joshi et al., 2008), and our serum re-stimulation results also indicate 
elevated Akt activity, as well as augmented levels of phospho-Mdm2 (S166), 
which invariably translates to lower p53 levels, in Par-4-/- cells in comparison 
to that in Par-4+/+ cells. Taken collectively, our results suggest that loss of 
Par-4-mediated Akt inhibition, and consequent elevation in Mdm2 activity, is 
responsible for decreased p53 expression and transcriptional activity; 
impaired p53 stabilization in response to genotoxic stresses, such as 
treatment with 5-FU and IR; and increased threshold for apoptosis induction 
in response to 5-FU and IR observed in Par-4-null cells. This work, therefore, 
provides a novel mechanistic insight into how Par-4 loss or down-regulation 
could be associated with therapy resistance in tumors possessing wild-type 
p53.  
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Fig. 3.1: Par-4-null cells are resistant to apoptosis by 5-FU or IR 
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Figure 3.1: Par-4-null cells are resistant to apoptosis by 5-FU or IR 
(A) Par-4-null MEFs demonstrate increased resistance to 5-FU treatment. 
Par-4+/+ and Par-4-/- MEFs were treated with indicated doses of 5-FU for 
24 hours, and the cells were scored for apoptosis by ICC for DAPI and 
active caspase-3 staining. 
(B) Par-4-null MEFs demonstrate increased resistance to IR. Par-4+/+ and 
Par-4-/- MEFs were exposed to 2, 4 or 6 Grays (Gy) of radiation for 24 
hours, and apoptosis was assayed by ICC for DAPI and active caspase-3. 
(A, B) Asterisk (**) indicates statistical significance (P < 0.001) based on two-way 
ANOVA followed by Bonferroni correction. 
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Fig. 3.2: Stress-inducible p53 stabilization and function is compromised in 
Par-4 loss 
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Fig. 3.2: Stress-inducible p53 stabilization and function is compromised in 
Par-4 loss 
(A) Par-4 is required for p53 accumulation after 5-FU treatment. Par-4+/+ 
and Par-4-/- MEFs were treated with either 10μM 5-FU or with vehicle 
control, DMSO. Cell lysates were harvested at the indicated time points 
and analyzed for p53 and Egr-1 expression by western blotting. Actin is 
used as loading control. 
(B) Par-4 is required for p53 accumulation after exposure to IR. Par-4+/+ 
and Par-4-/- MEFs were treated with 2, 4, and 6 Gy radiation, and the 
lysates were harvested 30 minutes or 90 minutes after exposure to IR. 
The whole cell lysates were subjected to western blotting and analyzed for 
p53 expression. Actin is used as loading control. 
(C) P53 transcriptional activity is attenuated in Par-4-null situation. Par-
4+/+ and Par-4-/- MEFs were transfected with either empty luciferase 
construct (pGL3-luc) or with a luciferase construct driven by p53 response 
elements (p53-luc). 24 hours later, cell extracts were assayed for 
luciferase activity, which is expressed as fold induction over basal activity 
produced by empty luc vector pGL3-luc. 
(D) P53 replenishment in Par-4-null cells partially rescues the apoptotic 
potential of 5-FU. Par-4-/- MEFs were infected with adenoviral constructs 
expressing either GFP, or GFP-p53 or GFP-Par-4 proteins. 18 hours after 
infection, cells were treated with the indicated doses of 5-FU for 24 hours, 
and assayed for apoptosis by DAPI positivity of pyknotic nuclei. 
(C, D) Asterisk (**) indicates statistical significance (P < 0.001) based on two-way 
ANOVA. 
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Fig. 3.3: Par-4 is required for p53 protein stability under basal conditions 
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Fig. 3.3: Par-4 is required for p53 protein stability under basal conditions 
(A) Basal expression of p53 is reduced in Par-4-null situation. Par-4+/+ 
and Par-4-/- cell lysates, as well as protein extracts prepared from the 
indicated organs harvested from Par-4+/+ and Par-4-/- mice were subjected 
to western blotting and probed for p53, Par-4 and actin. 
(B) Par-4 induces p53 protein stability. Par-4-/- MEFs were transduced with 
Par-4 expressing adenoviral construct. Cell lysates were collected 24 
hours after infection and analyzed by western blotting. 
(C) Par-4 is required for stability of wild-type, but not mutant, p53. A549 
and HOP92 lung cancer cells were infected with lentiviral particles 
containing either control shRNA (Con sh) or Par-4 shRNA (Par-4 sh) in 
order to silence Par-4 expression. Cells stably expressing the desired 
shRNA were selected by Puromycin treatment, and the lysates were 
analyzed for the expression of p53 by western blotting. A549 and HOP92 
cells stably expressing either Control or Par-4 shRNA were prepared by 
Dr. Sunil Nooti. 
(D) Par-4 does not regulate p53 RNA levels. Total RNA was extracted from 
lungs harvested Par-4+/+ and Par-4-/- mice, and subjected to reverse 
transcriptase PCR (RT-PCR) for analysis of p53 mRNA levels. 18S RNA 
is used as control. 
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Fig. 3.4: Par-4 loss results in elevated Mdm2 activity 
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Fig. 3.4: Par-4 loss results in elevated Mdm2 activity 
(A) p53 protein stability is reduced in the absence of Par-4 in primary 
MEFs. Par-4+/+ and Par-4-/- MEFs were treated with Cycloheximide (CHX), 
inhibitor of de novo protein synthesis, at the concentration of 10μg/ml. Cell 
lysates were harvested at the indicated time points and analyzed by 
western blot for the indicated proteins. 
(B) P53 protein stability is reduced in the absence of Par-4 in lung 
cancer cells. A549 cells (possessing wild-type p53) expressing either 
control shRNA or shRNA for Par-4 were treated with 10μg/ml 
Cycloheximide or vehicle control; cell lysates were harvested at indicated 
time points and subjected to western blot to analyze p53 protein. 
(C) Par-4 does not affect stability of mutant p53. HOP92 cells (possessing 
mutant p53) expressing either control shRNA or shRNA for Par-4 were 
treated with 10μg/ml Cycloheximide or vehicle control; cell lysates were 
harvested at indicated time points and subjected to western blot to 
analyze p53 protein. 
(D) P53 stability caused by Par-4 loss is rescued by Mdm2 inhibition. 
Par-4+/+ and Par-4-/- MEFs were pre-treated for 24 hours, and then treated 
with CHX for the indicated time points. Cell lysates were analyzed by 
western blotting. 
(E) Par-4 inhibits Akt-mediated phosphorylation of Mdm2 at S166. Par-
4+/+ and Par-4-/- MEFs were serum starved for 4 hours, and re-stimulated 
with 10% serum for short time periods in order to activate Akt. Cell lysates 
were collected at the indicated time points, and analyzed for the indicated 
proteins and phospho-proteins by western blotting.  
(F) Akt activity induces Mdm2 (S166) phosphorylation. Wild-type (WT) 
cells and cells expressing constitutively active form of Akt were lysed, 
harvested, and the lysates were subjected to western blotting and probed 
for the indicated proteins. Performed by Nikhil Hebbar.  
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CHAPTER FOUR: DISCUSSION AND FUTURE DIRECTIONS 
 
Selectivity towards cancer cells is perhaps the most desirable, and yet, the most 
elusive trait sought after in cancer therapy. The tumor suppressor Par-4, because 
of its unique cancer cell-specific apoptotic action, presents considerable 
therapeutic promise. In addition, Par-4 is secreted, and can act both 
intracellularly (both in the cytoplasm and the nucleus) and extracellularly to 
induce apoptosis specifically in cancer cells. The tumor suppressor p53, rightfully 
titled “the guardian of the genome”, holds the reins to a broad range of effector 
functions that contribute to its tumor suppressive effects. P53 transcriptionally 
controls and co-ordinates critical processes like cell cycle arrest, cellular 
senescence and apoptosis; and its emerging role in other important processes 
like autophagy and cellular metabolism is being increasingly chronicled. This 
dissertation work describes a fascinating cross-talk between these two tumor 
suppressors wherein they mutually regulate different facets of each other’s 
functions. Par-4, which is secreted in response to p53 activation, executes the 
paracrine apoptotic effect of p53 in a cancer cell-selective manner (chapter 2).  
Par-4, on the other hand, plays a role in p53 stabilization; and this mechanism 
probably serves to explain the apoptosis resistance conferred by par-4 loss to 
genotoxic insults that normally induce p53-dependent apoptosis (chapter 3). 
Reciprocal interactions between the tumor and its microenvironment, and the role 
of a supportive, reactive stroma in the development, progression and metastasis 
of tumors have been well documented. Lately, many studies have reported that 
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wild-type p53 in the stroma inhibits tumor growth, and that tumor progression 
selects for inactivation of p53 in the stromal compartment, particularly in cancer 
associated fibroblasts (CAFs) (Hill et al., 2005; Kiaris et al., 2005; Kurose et al., 
2002). Most of these studies, however, have been largely descriptive, and the 
mechanism whereby wild-type p53 in the fibroblasts could exert inhibitory effect 
on tumor growth is yet to be addressed.  
Our findings in chapter 2 reveal that Par-4, a tumor suppressor with potent 
apoptotic activity towards cancer cells, is secreted in response to p53 activation, 
and mediates the paracrine tumor suppressive effects of p53 (Figure 4.1). Since 
p53 function is frequently compromised in human cancers due to deletion or 
mutation of Tp53 gene, it is obvious that p53 protein in such scenarios will not be 
amenable to activation by Mdm2 inhibitor Nutlin-3a and NF-κB inhibitor PS1145. 
Therefore, we circumvented that problem by empowering the normal cells 
(normal fibroblasts which possess wild-type p53) to induce Par-4 secretion. Our 
experiments with mice indicate that a single injection of Nutlin-3a+PS1145 builds 
up adequate Par-4 in the serum to cause ex vivo apoptosis of cancer cells. Like 
p53, other molecular regulators of Par-4 secretion can be identified, and then 
pharmacologically targeted to induce Par-4 secretion from normal cells. In fact, a 
recent publication identified one such target, vimentin, which can be inhibited by 
Arylquin 1, to enhance Par-4 secretion (Burikhanov et al., 2014b). Therefore, 
identification of such molecular targets opens up avenues for rational drug design 
and development of Par-4 ‘secretagogues’ which promise immense therapeutic 
potential.  
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Our results suggest that Par-4 secretion in response to Nutlin-3a+PS1145 is 
induced by p53-mediated repression of UACA, a binding partner of Par-4. 
Binding of Par-4 by UACA results in Par-4 sequestration; and inhibition of UACA 
expression either by p53-mediated transcriptional repression or by NF-κB 
inhibition can have two consequences: 
a) In cancer cells: Liberation of Par-4 from sequestration by UACA, and an 
increase in the expression of Par-4 receptor GRP78 on the surface of 
cancer cells, rendering them more sensitive to extracellular Par-4-
mediated apoptosis (Burikhanov et al., 2013). 
b) In cells with intact p53 pathway: Liberation of Par-4 from sequestration by 
UACA, and an increase in Par-4 secretion. 
Our results with NF-κB inhibitors showing UACA down-regulation and enhanced 
Par-4 secretion from normal wild-type fibroblasts may have wider implications. 
Interestingly, UACA was identified as a protein up-regulated in inflammatory 
disease (panuveitis) (Yamada et al., 2001), and is positively regulated by NF-κB 
activity (Tran et al., 2010). By logical extension, then, we can hypothesize that 
drugs with anti-inflammatory properties (for example, NSAIDs) will be able to 
induce Par-4 secretion. Although NSAIDs are known to inhibit the enzymes 
cyclooxygenase-1 and/or -2 (COX-1, COX-2), some NSAIDs such as Aspirin, 
Sodium salicylate, Sulfasalazine, Sulindac (Yamamoto and Gaynor, 2001), and 
Ibuprofen (Greenspan et al., 2011) also inhibit NF-κB-mediated transcriptional 
activation.  
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Meta analyses of epidemiological data collected from different patient cohorts 
have discussed potential chemo-preventive effects associated with NSAID use 
against tumors at various sites, including prostate, breast, lung, brain, and 
melanoma (Liu et al., 2014a). In addition, these agents are also known to induce 
regression of adenomatous polyps of the colon and prevent development of 
colon cancer (Yamamoto and Gaynor, 2001). It will be interesting to examine if 
NF-κB inhibition by NSAIDs will result in elevated Par-4 secretion, and better still, 
to investigate if the chemo-preventive potential demonstrated by the use of these 
NSAIDs can be associated with the increase in Par-4 secretion. Data from Par-
4/SAC transgenic mice indicate an increased resistance to cancer with elevated 
serum levels of Par-4 protein. Considering cancer cell-specific apoptotic nature 
and tumor suppressive function of Par-4, it is possible that there is a correlation 
between secreted Par-4 and cancer risk, which may constitute an important 
aspect in Par-4 research.  
A particularly intriguing aspect of cross-talk between Par-4 and p53 is regulation 
of p53 stabilization by Par-4 (chapter 3). Using Par-4 wild-type and Par-4-null 
MEFs, we show that Par-4-null cells are significantly resistant to apoptosis by 
genotoxic agents such as IR and 5-FU, in spite of the fact that both sets of MEFs 
possess wild-type p53. It is well established that treatment with IR or 5-FU results 
in p53 stabilization/accumulation, and ultimately leads to p53-dependent 
apoptosis (Lowe et al., 1993a; Lowe et al., 1993b; Mirzayans et al., 2013). Even 
though apoptosis resistance conferred by Par-4 loss or down-regulation has 
been well studied, we show for the first time that p53 stress response is severely 
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attenuated in the absence of Par-4. Our results indicate that Par-4 loss leads to 
elevated Mdm2 activity, as judged by remarkable increase in Mdm2 (S166) 
phosphorylation, thereby resulting in reduced p53 stability (Figure 4.2). These 
results might have implications in therapy resistance shown by some cancers 
bearing wild-type p53. 
Renal cell carcinoma (RCC) is one of the few types of cancers that retain wild-
type p53. In fact, existing data suggests that approximately 86% of RCC contain 
wild-type p53. However, RCC is also characterized by increased co-expression 
of Mdm2; and such co-expression pattern is linked with poor disease prognosis 
(Polanski et al., 2014). Despite majority of RCC cases possessing wild-type p53, 
this disease exhibits exceptionally high resistance to radiation and chemotherapy 
(Cook et al., 1999). It is interesting to note that over 70% of human RCC show 
significant down-regulation of Par-4. Furthermore, replenishment of Par-4 protein 
into RCC cell lines established from two different RCC tumors restored 
therapeutic sensitivity of these cells to the apoptotic effects of Adriamycin and 
TNF- α (Cook et al., 1999). This result definitely indicates that apoptotic response 
of RCC cell lines is regained with Par-4 restoration. On the other hand, p53 
stabilization using Mdm2 inhibitor Nutlin-3 is reported to induce growth arrest and 
senescence in RCC cells (Polanski et al., 2014). Was p53 activation/stabilization 
in response to Adriamycin compromised in RCC cells containing low Par-4? 
Does Par-4 down-regulation in RCC correlate with therapy resistance and poor 
disease outcome? Do Par-4 down-regulation and Mdm2 over-expression show 
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an inverse correlation? These not only constitute interesting research questions 
for the future, but might influence the choice of therapy used for RCC.  
Dudley et. al. reported a similar phenomenon of impaired p53 function in tumor-
associated stromal cells from A375 melanoma and PC3 prostate carcinoma 
xenografts and a spontaneous prostate tumor model TRAMP. They found that, 
upon treatment with p53-activating agents such as Etoposide and Vincristine, 
these tumor-associated stromal cells failed to accumulate p53, and showed 
increased resistance to growth inhibitory and apoptotic effects of these drugs, 
despite the fact that p53 sequence remained wild-type. Such lack of response 
demonstrated by tumor-associated stromal cells is reminiscent of that shown by 
Par-4-null fibroblasts. Therefore, it may be worthwhile investigating if Par-4 status 
is altered in cancer-associated stroma during tumor progression, and examining 
whether such alteration, if present, has a bearing on how the stroma responds to 
therapy. 
It is known that the kind of effector function elicited by p53 is highly context 
dependent (Zilfou and Lowe, 2009). We now know that loss of Par-4 
compromises p53 pathway and renders cells more resistant to apoptosis. 
However, whether other p53-regulated processes, such as cell cycle arrest, 
senescence, autophagy, and cellular metabolism also get similarly affected by 
Par-4 loss remains to be investigated. In addition, is reduced stability of p53 in 
the absence of Par-4 solely due to Akt-mediated activation of Mdm2? It is also 
likely that Par-4 can directly bind and modulate Mdm2 activity, given our 
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observation of such strong inhibition of p53 expression due to Par-4 loss. Direct 
regulation of Mdm2 expression/activity by Par-4 also needs to be examined. 
In summary, the studies described in this dissertation elaborate how the mutual 
interplay between the two tumor suppressors p53 and Par-4 has helped: 
 Conceptualize a novel strategy of empowering normal cells to combat 
remote cancer cells by releasing a cancer cell-specific killer protein.  
 Elucidate the mechanism by which Par-4 loss may confer therapy 
resistance in cells that possess wild-type p53. 
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Figure 4.1: Par-4 mediates the paracrine apoptotic effect of p53 
 
 
 
 
Fig 4.1: Par-4 mediates the paracrine apoptotic effect of p53. P53 activation 
by Nutlin-3a and NF-κB inhibition by PS-1145 results in robust p53 activation, 
thereby leading to synergistic increase in Par-4 secretion. Extracellular Par-4 
then targets cancer cells in remote locations, thus executing the paracrine 
apoptotic effect of p53 in a cancer cell-specific manner. 
Adapted and modified from Burikhanov et. al., Cell Rep. 2014 Jan 30;6(2):271-7.  
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Figure 4.2: Par-4 regulates p53 stability 
 
 
 
Figure 4.2: Par-4 regulates p53 stability. The E3 ligase activity is enhanced by 
Akt, which in turn is inhibited by Par-4. In the absence of Par-4, Akt-mediated 
phosphorylation of Mdm2 at S166 activates it, and results in an increased rate of 
p53 degradation, as well as inhibition of p53 transcriptional activity. 
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